Severely Atrophic Mandible Reconstruction by Dental Implants and Modified “Tent Pole” Technique

Implants & Bone Grafting

Implant Surgery

Linkows’ Blade-Vent Implants: 29 Years of Successful Function
Goals & Scope

Journal of *Diagnoses & Treatment of Oral & Maxillofacial Pathology* goals to publish the cutting-edge and peer-reviewed articles on work in oral and maxillofacial surgery and neighboring specialties. The journal includes the following topics: implants surgery, head and neck imaging, microvascular and reconstructive surgery, oral and maxillofacial pathology, head and neck surgery/oncology, TMJ lesions/disorders, head and neck trauma, plastic surgery, pharmacology/drugs.

**Official Registered Multilingual Journal Name**
Diagnoses and Treatment of Oral and Maxillofacial Pathology
Журнал “Діагностика і лікування оральної та щелепно-лицової патології”
Журнал “Диагностика и лечение оральной и челюстно-лицевой патологии”

Registered in Ministry of Justice (Ukraine)
Registration Certificate: KB №22251-12151P
Issued on July 28, 2016
ISSN 2522-1965 (Online)
ISSN 2519-2086 (Print)

**2 (3) 2018**
**Circulation:** 1,000
**Frequency:** 4 times a year

The *journal* is included to the list of scientific professional publications (issued on December 28, 2017; protocol # 1714) of Ministry of Education and Science of Ukraine. In that *journal* the results of dissertation papers can be published for obtaining the degrees of Candidate and Doctor of Medical Sciences.

**Citations**
CrossRef, Google Scholar

**Founders**
Shupyk National Medical Academy of Postgraduate Education
PHEE “Kyiv Medical University”
OMF Publishing, LLC

**Investments**
Ellet E. (Ukraine)

**Marketing and Advertising**
Dushyna A.I. (Canada)

**Ukrainian Association for Maxillofacial and Oral Surgeons (UAMOS)**
4-a Prof Pidvysotskogo Street, Kyiv 01103, Ukraine.
Tel., fax: +38 (044) 528 35 17.
E-mail: info.uamos@gmail.com
UAMOS webpage: www.uamos.org

**Director of Journal Development Department**
Kilipiris E. (Greece/Slovakia)

**Members of Journal Development Department**
Burtyn O.V. (Ukraine)
Cruz R.L. (Brazil)
Kondratiu B.R. (Ukraine)
Mastakov O. (Ukraine)
Starodub Y. (New Zealand)
Zaramello Costa B. (Brazil)

**English Language Editors**
Grishko T. (United Kingdom)

**Ukrainian and Russian Language Editor**
Fesenko O.D. (Ukraine)

**Layout**
Smirnova L.Ie. (Ukraine)

**Scientific Adviser**
Goushcha O., PhD (USA)
Sirenko O.F., PhD, Assoc Prof (Ukraine)

**Director of Legal Department**
Popovych K.O. (Ukraine)
kostiantyn.popovych@dtjournal.org

**Associate Legal Advisers**
Vashulenko O.V. (Ukraine)
Vlasiuk T.O. (Ukraine)

**Is recommended by**
Ukrainian Association for Maxillofacial and Oral Surgeons, Ukrainian Association of Prophylactic and Children’s Stomatology, Ukrainian Association of Pathologists.

**Published by**
OMF Publishing, LLC
13-A Simferopolska Street, office 121, Kyiv, Ukraine, 02096
Tel: +38 (097) 301 55 92,
E-mail: omfpublishing@ukr.net
Instagram: omf_publishing
www.omfpublishing.com
Printed in Ukraine

The articles published in the Journal of *Diagnoses and Treatment of Oral and Maxillofacial Pathology* are distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

SUBSCRIPTION INDEX IN UKRAINE: 60077
Editor in Chief

Tymofieiev O.O.
ScD, Prof, Honored Science and Technology Worker of Ukraine. The chair of both the Department for Maxillofacial Surgery at the Shupyk National Medical Academy of Postgraduate Education & the Department of Oral and Maxillofacial Surgery at the PHEE "Kyiv Medical University", President of Ukrainian Association for Maxillofacial & Oral Surgeons. Director General in the American Biographical Institute (USA). Deputy Director General in the International Biographical Centre (England).

Address: 4-a Prof Pidvyotskogo Street, Kyiv 01103, Ukraine. Tel., fax: +38 (044) 528 35 17
tymofeev@gmail.com; @oleksii.tymofieiev

Deputy Editors in Chief

Fernandes R.P.
MD, DMD, FACS, FRCS(Ed), Prof, Departments of Oral & Maxillofacial Surgery; Orthopedics, Neurosurgery, & General Surgery. Director, Head & Neck Oncology and Microvascular Surgery Fellowship. Chief, Division of Head & Neck Cancer. College of Medicine. University of Florida.
Regent Ex Officio in the American College of Oral & Maxillofacial Surgeons.
Editorial Board Member, Journal – Oral and Maxillofacial Surgery Cases.
(Jacksonville, Florida, USA)

Savychuk N.O.
ScD, Prof, Honored Science and Technology Worker of Ukraine.
Vice-Rector for Science at Shupyk National Medical Academy of Postgraduate Education
(Kyiv, Ukraine)

Section Editors

Autoimmune Diseases
Naishtetik I.M., PhD
(Kyiv, Ukraine)
@irina_naishtetik
Benign Clinical Conditions
Tymofieiev O.O., ScD, Prof
(Ukraine)

Bone Augmentation Techniques
Casp N., Prof
(Jerusalem, Israel)

Craniofacial Deformities
Richardson S., Visiting Prof
(Nagercoil, Tamil Nadu, India)
@edsrichardson

Facial Feminization Surgery
Kojampan K.
(Los Angeles, California, USA)
@kojampan

Head & Neck Oncological Surgery
Todd Hanna
(New York, New York, USA)
@doctor.hanna

Head & Neck Radiology
Ahuja A.T., Prof
(Hong Kong, SAR, China)

Microvascular Surgery
Fernandes R.P., Prof
(Jacksonville, Florida, USA)

Mobs Surgery
Khan M., Assis Prof
(New York, New York, USA)
@khanmiikah6

MRONJ
Hatab N., PhD, Assis Prof
(Ras Al Khaimah, UAE)

Myofascial Pain/Disorders
Zhebulovych Z.Y., ScD, Assoc Prof
(Kyiv, Ukraine)

Orthognathic Surgery
Brinhole M.
(São Paulo, São Paulo, Brazil)

Osteosynthesis of Facial Bones
Kopchak A.V., ScD, Prof
(Kyiv, Ukraine)

Pathology
Tuffaha M.S., ScD, Prof
(Cottbus, Germany)

Pediatric Maxillofacial & Craniofacial Surgery
Steinberg B., PhD
(Jacksonville, Florida, USA)

Plastic Surgery
Fattahi T., Prof
(Jacksonville, Florida, USA)

Robotic Surgery
Salman S.O., Assis Prof
(Jacksonville, Florida, USA)
@ssalman

Salivary Glands Diseases
Lisova I.G., ScD, Prof
(Kharkiv, Ukraine)

TMJ Lesions/Disorders
Vasconcelos B.C., PhD, Prof
(Recife, Pernambuco, Brazil)

Trigeminal/Facial Nerve Trauma
Vesova O.P., ScD, Prof
(Kyiv, Ukraine)
Editorial Board

Ankin M.L., ScD, Prof (Kyiv, Ukraine)
Antonyshyn O.M., Prof (Toronto, Ontario, Canada)
Araujo M.M., Prof (São José dos Campos, São Paulo, Brazil)
Beridze B., PhD (Batumi, Georgia)
Bida V.I., ScD, Prof (Kyiv, Ukraine)
Bunnell A., Assis Prof (Jacksonville, Florida, USA)
Cantero D.R. (Madrid, Spain)
Chichua Z., ScD, Prof (Tbilisi, Georgia)
Constantini S., Prof (Tel Aviv, Israel)
Doroshenko O.M., ScD, Prof (Kyiv, Ukraine)
Gichka S.G., ScD, Prof (Kyiv, Ukraine)
Guliuk A.G., ScD, Prof (Odesa, Ukraine)
Hala Zakaria, PhD, Assoc Prof (Ras Al Khaimah, UAE)
Horn F., PhD (Bratislava, Slovak Republic)
Iefymenko V.P., PhD, Assoc Prof (Kyiv, Ukraine)
Ivnev B.B., ScD, Prof (Kyiv, Ukraine)
Kabanova A.A., PhD, Assoc Prof (Vitebsk, Belarus)
Kabat M., PhD (Bratislava, Slovak Republic)
Komský M.P., ScD, Prof (Dnipro, Ukraine)
Kulbashtra Y.A., ScD, Prof (Kyiv, Ukraine)
Lesnukhin V.I., PhD, Assoc Prof (Gothenburg, Sweden)
Lutskaia I.K., ScD, Prof Laureate of State Prize for Republic of Belarus (Minsk, Belarus)
Maksymchka S.V., PhD, Assoc Prof (Kyiv, Ukraine)
Mazen Tamim, PhD (Amman, Jordan)
Medvediev V.E., ScD, Prof Honored Science & Technology Worker of Ukraine (Kyiv, Ukraine)
Pavlenko O.V., ScD, Prof Honored Science & Technology Worker of Ukraine (Kyiv, Ukraine)
Peredkov K.I., PhD, Assoc Prof (Kyiv, Ukraine)
Petrik M. (Bratislava, Slovak Republic)
Potapchuk A.M., ScD, Prof Honored Science & Technology Worker of Ukraine (Uzhhorod, Ukraine)
Protsyk V.S., ScD, Prof (Kyiv, Ukraine)
Ragimov C.R., ScD, Prof (Baku, Azerbaijan)
Ruslin M. (Makassar, Indonesia)
Savychuk O.V., ScD, Prof (Kyiv, Ukraine)
Stanko P., PhD, Prof (Bratislava, Slovakia)
Szabó G., Prof Emeritus (Budapest, Hungary)
Tkachenko P.I., ScD, Prof (Poltava, Ukraine)
Trnka J., PhD, Assoc Prof (Bratislava, Slovak Republic)
Tsakhmister Y.V., ScD, Prof Corresponding Member in NAPS of Ukraine (Kyiv, Ukraine)
Tymofiev O.O., ScD, Assoc Prof (Kyiv, Ukraine)
Ushko N.O., ScD, Assoc Prof (Kyiv, Ukraine)
Vares Y.E., ScD, Prof (Lviv, Ukraine)
Voronenko Y.V., Academician of NAMS, ScD, Prof Honored Science & Technology Worker of Ukraine (Kyiv, Ukraine)
Iakovenko L.M., ScD, Prof (Kyiv, Ukraine)
Zaritska V.I., PhD, Assoc Prof (Kyiv, Ukraine)
Jezzini A.A., PhD, Assoc Prof (Beirut, Lebanon)

Web & Social Media Editor
Monteiro J.L. (Recife, Pernambuco, Brazil)
j.i.monteiro@dtjournal.org
@joaoluizmonteiro

Managing Editor
Fesenko I.e.I., PhD, Assis Prof (Kyiv, Ukraine)
i.e.fesenko@dtjournal.org
@dr_eugenfesenko

Review of Events
Khadem A.A. (Kyiv, Ukraine)
ariana.khadem@dtjournal.org
@aria_ni

Statistical Editor
Petasyuk G.A., ScD, Leading Researcher (Kyiv, Ukraine)

Books Scan (Radiology)
Babkina T.M., ScD, Prof (Kyiv, Ukraine)

Assistant Managing Editors
Szmirnova I. (Budapest, Hungary)
Dushyn I.I. (Vancouver, British Columbia, Canada)
**Composition:**
active substance: **benzydamine hydrochloride**;
100 mL of solution contain benzydamine hydrochloride 0.15 g;
excipients: ethanol 96%, glycerol, methyl parahydroxybenzoate (E 218), flavor (menthol), saccharin, sodium hydrocarbonate, Polysorbate 20, Quinoline Yellow (E 104), Patent Blue V (E 131), purified water.

**Dosage form.** Oromucosal solution.
**Basic physical and chemical properties:** a clear green liquid with a typical mint flavor.

**Pharmacotherapeutic group.** Dental preparations. Other agents for local oral treatment.
**ATC code:** A01A D02.

**Pharmacological properties.**
**Pharmacodynamics.**
Benzydamine is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and antiexudative properties.
Clinical studies have shown that benzydamine is effective in the relief of symptoms accompanying localized irritation conditions of the oral cavity and pharynx. Moreover, benzydamine has anti-inflammatory and local analgesic properties, and also exerts a local anesthetic effect on the oral mucosa.

**Pharmacokinetics.**
Absorption through the oral and pharyngeal mucosa has been proven by the presence of measurable quantities of benzydamine in human plasma. However, they are insufficient to produce any systemic pharmacological effect. The excretion occurs mainly in urine, mostly as inactive metabolites or conjugated compounds.
When applied locally, benzydamine has been shown to cumulate in inflamed tissues in an effective concentration due to its ability to permeate through the mucous membrane.

**Clinical particulars.**
**Indications.**
Symptomatic treatment of oropharyngeal irritation and inflammation; to relieve pain caused by gingivitis, stomatitis, pharyngitis in dentistry after tooth extraction or as a preventive measure.

**Contraindications.**
Hypersensitivity to the active substance or to any other ingredients of the product.

**Interaction with other medicinal products and other types of interaction.**
No drug interaction studies have been performed.

**Warnings and precautions.**
If sensitivity develops with long-term use, the treatment should be discontinued and a doctor should be consulted to get appropriate treatment.
In some patients, buccal/pharyngeal ulceration may be caused by severe pathological processes. Therefore, the patients, whose symptoms worsen or do not improve within 3 days or who appear feverish or develop other symptoms, should seek advice of a physician or a dentist, as appropriate.
Benzydamine is not recommended for use in patients hypersensitive to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs).
The product can trigger bronchospasm in patients suffering from or with a history of asthma. Such patients should be warned of this.
For athletes: the use of medicinal products containing ethyl alcohol might result in positive antidoping tests considering the limits established by some sports federations.

**Use during pregnancy or breast-feeding**
No adequate data are currently available on the use of benzydamine in pregnant and breastfeeding women. Excretion of the product into breast milk has not been studied. The findings of animal studies are insufficient to make any conclusions about the effects of this product during pregnancy and lactation.
The potential risk for humans is unknown.
**TANTUM VERDE** should not be used during pregnancy or breast-feeding.

**Effects on reaction time when driving or using machines**
When used in recommended doses, the product does not produce any effect on the ability to drive and operate machinery.
Method of administration and doses.
Pour 15 mL of TANTUM VERDE solution from the bottle into the measuring cup and gargle with undiluted or diluted product (15 mL of the measured solution can be diluted with 15 mL of water). Gargle 2 or 3 times daily. Do not exceed the recommended dose.

Children.
The product should not be used in children under 12 years due to a possibility of ingestion of the solution when gargling.

Overdosage.
No overdose has been reported with benzydamine when used locally. However, it is known that benzydamine, when ingested in high doses (hundreds times higher than those possible with this dosage form), especially in children, can cause agitation, convulsions, tremor, nausea, increased sweating, ataxia, and vomiting. Such acute overdose requires immediate gastric lavage, treatment of fluid/salt imbalance, symptomatic treatment, and adequate hydration.

Adverse reactions.
Within each frequency group, the undesirable effects are presented in order of their decreasing seriousness.

Adverse reactions are classified according to their frequency: very common (≥ 1/10); common (≥ 1/100 to <1/10); uncommon (≥ 1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); very rare (<1/10,000); frequency unknown (cannot be estimated from the available data).

Gastrointestinal disorders: rare – burning mouth, dry mouth; unknown – oral hypesthesia, nausea, vomiting, tongue edema and discoloration, dysgeusia.

Immune system disorders: rare – hypersensitivity reaction, unknown - anaphylactic reaction.

Respiratory, thoracic and mediastinal disorders: very rare – laryngospasm; unknown – bronchospasm.

Skin and subcutaneous tissue disorders: uncommon – photosensitivity; very rare – angioedema; unknown – rash, pruritus, urticaria.

Nervous system disorders: unknown – dizziness, headache.

TANTUM VERDE contains methyl parahydroxybenzoate, which can cause allergic reactions (including delayed-type reactions).

Shelf life. 4 years.

Storage conditions.
Do not store above 25°C. Keep out of reach of children.

Packaging.
120 mL of solution in a bottle with a measuring cup; 1 bottle per cardboard box.

Dispensing category.
Over-the-counter medicinal product.

Manufacturer.

Location of the manufacturer and its business address. Via Vecchia del Pinocchio, 22 – 60100 Ancona (AN), Italy.

Date of the last revision of the text.
September 26, 2018.

Information leaflet is APPROVED by Order of the
Ministry of Health of Ukraine
No. 636 dated 01.10.2015
Registration Certificate
No. UA/3920/01/01
Subscription in Ukraine

A Journal of Diagnostics & Treatment of Oral & Maxillofacial Pathology is published quarterly. A subscription for individuals and institutions to the print version of the Journal is performed both in any state post offices of Ukrposhta at the territory of Ukraine and online via website www.presa.ua

A SUBSCRIPTION INDEX IS: 60077

<table>
<thead>
<tr>
<th>Number of Issues (Numbers)</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 issues per second half of the year 2018 (September, December)</td>
<td>US $ 13.84 (UAH 391.00)</td>
</tr>
<tr>
<td>2 issues per year 2019 (March, June or September, December)</td>
<td>US $ 13.84 (UAH 391.00)</td>
</tr>
<tr>
<td>4 issues per year 2019 (March, June, September, December)</td>
<td>US $ 27.68 (UAH 782.00)</td>
</tr>
</tbody>
</table>
# Content

of the Volume 2 (Issue 3) 2018

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>Publisher and Editorial Office Information</td>
</tr>
<tr>
<td>A2</td>
<td>Editorial Board</td>
</tr>
<tr>
<td>A6</td>
<td>Subscription in Ukraine</td>
</tr>
<tr>
<td>A7</td>
<td>Content</td>
</tr>
<tr>
<td>A9</td>
<td>Review of Event</td>
</tr>
<tr>
<td></td>
<td>Evangelos G. Kilipiris</td>
</tr>
<tr>
<td></td>
<td>Editorial</td>
</tr>
<tr>
<td>106</td>
<td>Minister Brings the Best World Standards to the Ukrainian Scientific Publications</td>
</tr>
<tr>
<td></td>
<td>Oleksii O. Tymofieiev</td>
</tr>
<tr>
<td></td>
<td>Editorial</td>
</tr>
<tr>
<td>112</td>
<td>One of the Highest World Privileges</td>
</tr>
<tr>
<td></td>
<td>Ievgen I. Fesenko</td>
</tr>
<tr>
<td></td>
<td>Dental Implants and Jaw Augmentation Technique</td>
</tr>
<tr>
<td>113</td>
<td>Reconstruction of Severely Atrophic Mandible by Installing Dental Implants Using the Modified “Tent Pole” Technique: Case Report</td>
</tr>
<tr>
<td></td>
<td>Rodrigo Tavares de Sá, Lincoln Lara Cardoso, Italo Cordeiro de Toledo, Luis Gustavo Jaime Paiva, Guilherme Romano Scartezini, and Giovanni Gasperini</td>
</tr>
<tr>
<td></td>
<td>Dental Implants</td>
</tr>
<tr>
<td>118</td>
<td>Linkows' Blade-Vent Implants Continue to Work After Twenty-Nine Years: Case Report</td>
</tr>
<tr>
<td></td>
<td>Zinaida Y. Zhehulovych, Ievgen I. Fesenko, and Nadim Al-Makhamid</td>
</tr>
<tr>
<td></td>
<td>Salivary Glands, Autoimmune Disease, Pathology</td>
</tr>
<tr>
<td>122</td>
<td>Correlation and Accuracy of Labial Minor Salivary Gland Biopsy in the Establishment of Diagnosis in Patients With Suspected Sjögren's Syndrome</td>
</tr>
<tr>
<td></td>
<td>Evangelos G. Kilipiris, Katarina Machalekova, Georgia Fountoulaki, Kareen Andrade, Nikolaos Mantziaris, and Peter Stanko</td>
</tr>
<tr>
<td></td>
<td>MRONJ</td>
</tr>
<tr>
<td>132</td>
<td>Medication-Related Osteonecrosis of the Jaw (MRONJ): Clinical Manifestations and Radiographic Signs</td>
</tr>
<tr>
<td></td>
<td>Oleksii O. Tymofieiev and Oleksandr O. Tymofieiev</td>
</tr>
<tr>
<td></td>
<td>Trigeminal Nerve Disorders</td>
</tr>
<tr>
<td>142</td>
<td>Approaches to the Systematization of the Trigeminal Nerve Disorders</td>
</tr>
<tr>
<td></td>
<td>Oleksii O. Tymofieiev, Olena P. Vesova, and Natalia O. Ushko</td>
</tr>
<tr>
<td></td>
<td>Obituary, Plastic Surgery</td>
</tr>
<tr>
<td>148</td>
<td>Obituary for Dr. José Guerrerosantos: A Teacher Who Continues to Live in the Works of His Disciples</td>
</tr>
<tr>
<td></td>
<td>Julio Palacios Juárez and Ievgen I. Fesenko</td>
</tr>
<tr>
<td>A10</td>
<td>Future Events</td>
</tr>
<tr>
<td>A13</td>
<td>Submission of Articles</td>
</tr>
<tr>
<td>A16</td>
<td>Association Information</td>
</tr>
<tr>
<td>A17</td>
<td>Disclaimer</td>
</tr>
</tbody>
</table>
Journals’ cover images (virtual surgical planning for a sleep apnea patient treatment using custom made cutting guides and plates for sagittal split osteotomy) are courtesy of:

Dr. Diego Sergio Rossi (upper image: on the right) and Dr. Michele Romano (upper image: on the left)

(Department of Biomedical, Surgical & Dental Sciences
(Head – Prof Giannì A.B.)
University of Milan
Maxillo-Facial & Dental Unit (Head – Prof Giannì A.B.)
Fondazione Ca’ Granda IRCCS Ospedale Maggiore Policlinico of Milan); Milan, Italy

E-mail: michele.romano@unimi.it
Instagram: maxillofacialpics
The best way only being at the Congress… at 24th Congress of the European Association for Cranio-Maxillo-Facial Surgery (www.eacmfs2018.com). 18-21 of September was the hottest and the most anticipated days among OMF and H&N surgeons, residents, and trainees. In that days all roads come to Munich. The city brought so much new connections, inspiration and so needed motivation. Wolff, Rodriguez (Fig 2), Fernandes, Rana, D’Cruz, Turvey, Gilbert, Parmar et al, those names continue to sound in our minds, being the guiding stars in our surgical life. And we start dreaming again… dreaming about 25th Congress in Paris (September 15-18, 2020).

Evangelos G. Kilipiris, DMD
Director, Journal Development Department
Thessaloniki, Greece/Bratislava, Slovak Republic
E-mail: varonos@live.co.uk; Instagram: evangeloskilipiris
Editorial

Minister Brings the Best World Standards to the Ukrainian Scientific Publications*

Oleksii O. Tymofieiev*
Chair, Department of Maxillofacial Surgery, Stomatology Institute, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine (ScD, Prof)

“To improve is to change, so to be perfect is to have changed often”
— Winston Churchill, Prime Minister, United Kingdom from 1940 to 1945 from 1951 to 1955

Improvement is always great. Improvement in the science of oral and maxillofacial surgery is more than great. Especially, when that improvement is supported and implemented at the highest level of Government. Order #32 of the Ministry of Education and Science of Ukraine (issued January 15, 2018) accelerate the movement of the Ukrainian scientific publications to the best positions in the extremely dynamic world of scientific publication. The purpose of that Editorial is to highlight the features of a new Order.

According the Order all Ukrainian scientific publications, which are in the List of scientific professional publications of Ukraine, divided into three categories till the year 2020: “A”, “B”, and “C” [1]. After March 2020 there will be only two categories: “A” and “B”.

The item 3 (Fig 2A) of the Order is established that the scientific professional publications included in the List of scientific professional publications of Ukraine on the day of the entry into force of this Order shall be assigned a category “C” for a period of two years (till March, 2020). If, during this period, the categories “C” to the Ministry of Education and Science have submitted documents confirming compliance with the requirements for the assignment of category “A” or category “B”, they are assigned these categories [1].

The item 6 (Fig 2B) (Rule of the Formation of the List of scientific professional publications of Ukraine) tell us:

To the category “A” are included scientific publications that included to the scientometric databases Scopus® and/or Web of Science Core Collection (Fig 1) [2, 3]. To the category “B” are included the scientific publications that meet the requirements of subclauses 1-8 of item 6.

All advantages and disadvantages of a new Order the readers and workers of the editorial offices can easily find in the Rule of the Formation of the List of scientific professional publications of Ukraine (Fig 2B-E).

What I can tell on behalf of Editorial Board of the Diagnostics & Treatment of Oral & Maxillofacial Pathology that other great international journals of head & neck area (Plastic & Reconstructive Surgery, impact factor – 3.475; Head & Neck, impact factor – 2.471; Journal of Oral & Maxillofacial Surgery, impact factor – 1.779; etc.) are completely supporting those key item of a new Ministers’ Order being included to those scientometric databases. So, it`s definitely a right Order that will help to move the surgical science forward much faster.

* This manuscript has not been presented
* Corresponding author. Department of Maxillofacial Surgery, Stomatology Institute, Shupyk NMAPE, 4-a Pylypotskogo Street, Kyiv 01103, Ukraine.
Tel., fax: +38 (044) 528 35 17.
E-mail address: tymofieiev@gmail.com (Oleksii O. Tymofieiev)
Instagram: oleksii.tymofieiev; dt_journal
http://dx.doi.org/10.23999/j.dtomp.2019.3.1
МИНІСТЕРСТВО ОСВІТИ І НАУКИ УКРАЇНИ

НАКАЗ

15.01.2018 № 32

Зареєстровано в Міністерстві юстиції України
06 лютого 2018 р.
за № 148/31600

Про затвердження Порядку формування Переліку наукових фахових видань України

Відповідно до пункту 8 Положення про Міністерство освіти і науки України, затвердженого постановою Кабінету Міністрів України від 16 жовтня 2014 року № 630, та пункту 12 Порядку присудження наукових ступенів, затвердженого постановою Кабінету Міністрів України від 24 липня 2013 року № 567, НАКАЗУЮ:

1. Затвердити Порядок формування Переліку наукових фахових видань України, що додається.

2. Визнати таким, що втратив чинність, наказ Міністерства освіти і науки, молоді та спорту України від 17 жовтня 2012 року № 1111 «Про затвердження Порядку формування Переліку наукових фахових видань України», зареєстрований в Міністерстві юстиції України 02 листопада 2012 року за № 1850/22162.

3. Установити, що науковим фаховим виданням, включенням до Переліку наукових фахових видань України на день набрання чинності цим наказом, присвоюється категорія «В» строком на два роки. Якщо протягом цього строку стосовно видань категорії «В» до МОН подані документи, що підтверджують дотримання вимог для присвоєння категорії «А» або категорії «Б», їм присвоюються ці категорії.

4. Департаменту атестації кадрів вищої кваліфікації та ліцензування (Шевцов А.Г.) забезпечити державну реєстрацію цього накazu в Міністерстві юстиції України в установленому законодавством порядку.

5. Контроль за виконанням цього накazu покласти на першого заступника Міністра Ковтунця В.В.

6. Цей наказ набирає чинності з дня його офіційного опублікування.

Міністр

Л.М. Гриневич

FIGURE 2. (A) Cropped copy of the 1st page of Order of the Ministry of Education and Science of Ukraine (issued January 15, 2018). Item 3 is indicated by red line. Source: the date received from www.zakon5.rada.gov.ua [1], September 10, 2018. (Fig 2 continued on next page.)
ПОРЯДОК
формування Переліку наукових фахових видань України

1. Цей Порядок встановлює умови формування Переліку наукових фахових видань України (далі - Перелік), а також класифікації та моніторингу видань, включених до Переліку. Видання, яке відповідає визначеним у цьому Порядку вимогам, включається до Переліку.

2. Метою об’єктивної оцінки, класифікації та моніторингу наукових фахових видань є підвищення якості опублікованої у них наукової інформації та інтеграція цих видань до світового наукового простору. Під публікацією розуміється випуск друкованого видання накладом не менше 50 примірників або оприлюднення видання в електронному вигляді в мережі Інтернет у форматі, не призначенному для редагування, з вільним або платним доступом.

3. Наукові фахові видання з Переліку застосовуються для:

1) розвитку вітчизняного наукового потенціалу та інтеграції його у світовий науковий простір;

2) створення простору якісної публічної комунікації вчених, зокрема якісного донесення результатів їх діяльності до вітчизняної і світової наукових спільнот;

3) офіційного визнання наукових публікацій, зокрема:

опублікування основних наукових результатів дисертацій здобувачами наукових ступенів та досліджень претендентів на присвоєння вчених звань;

врахування при оцінюванні результатів наукової діяльності закладів вищої освіти і наукових установ;

врахування при оцінюванні результатів наукової діяльності та атестації наукових та науково-педагогічних працівників;

врахування при оцінюванні проектів науково-дослідних робіт, поданих на конкурси для фінансування за кошти державного чи місцевих бюджетів.

4. Засновниками (співзасновниками) наукового фахового видання можуть бути суб’єкти наукової і науково-технічної діяльності, які діють відповідно до Закону України «Про наукову і науково-технічну діяльність», серед яких має бути принаймні одна юридична особа.

5. При включенні наукового періодичного видання до Переліку зазначаються спеціальність, за якою видання здійснює публікації.

6. До Переліку включаються наукові періодичні видання України, що входять до наукометричних баз Scopus та/або Web of Science Core Collection (категорія «A»), видання, які відповідають вимогам підпунктів 1-8 цього пункту (категорія «B»), і видання, які відповідають вимогам підпунктів 1-5 цього пункту, з урахуванням вимог підпункту 3 пункту 11 цього Порядку (категорія «В»):

1) наявність свідоцтва про державну реєстрацію засобу масової інформації із загальнодержавною та/або зарубіжною сферою його розповсюдження (для періодичних друкованих наукових видань).
EDITORIAL: MINISTER BRINGS THE BEST WORLD STANDARDS TO THE SCIENTIFIC PUBLICATIONS

2) ISSN-номер, що використовується для ідентифікації друкованого та/або електронного періодичного видання та дотримання заявленої періодичності;

3) присвоєння кожному опублікованому матеріалу міжнародного цифрового ідентифікатора DOI (Digital Object Identifier);

4) наявність web-сайта видання з українським та англійським інтерфейсами (інтерфейс може мати інші іноземні мови, пов'язані зі сферою поширення видання) або web-сторінки видання на web-сайті засновника (співзасновника) видання з такою інформацією:

полятика (мета та завдання) наукового видання;

склад редакційної колегії (редакційної ради (за наявності)) із зазначенням наукового ступеня, звання та основного місця роботи;

процедура рецензування та дотримання редакційної етики;

порядок оформлення та подання публікації для оприлюднення;

у разі відкритого доступу - повні тексти за умови розповсюдження за передплатою - інформації про умови доступу та анотації до кожної статті відповідно до змісту випусків, оприлюднених на web-сторінці видання;

якщо видання не є повністю англомовним, кожна публікація не англійською мовою супроводжується анотацією англійською мовою обсягом не менш як 1800 знаків, включаючи ключові слова. Якщо видання не є повністю україномовним, кожна публікація не україною мовою супроводжується анотацією українською мовою обсягом не менш як 1800 знаків, включаючи ключові слова;

5) розміщення на платформі «Наукова періодика України» в Національній бібліотеці України імені В.І. Вернадського НАН України та в Національному репозитарії академічних текстів у разі відкритого доступу електронних копій видання, а за умови розповсюдження за передплатою - повного бібліографічного опису та анотації до статей, які розміщуються у відповідних номерах видань, для формування реєстру академічних текстів;

6) забезпечення якісного незалежного рецензування поданих для публікації матеріалів вченими, які здійснюють дослідження за спеціальністю і мають за останні три роки не менше однієї публікації у виданнях, включених до Переліку, або закордонних виданнях, включених до Web of Science Core Collection та/або Scopus, або мати монографії чи розділи монографій, видани міжнародними видавництвами, що належать до категорій «A», «B» або «C» за класифікацією Research School for Socio-Economic and Natural Sciences of the Environment (SENSE); рецензії, підписані рецензентом звичайним або цифровим електронним підписом, мають зберігатися в редакції не менше трьох років;

7) наявність у складі редакційної колегії видання не менше семи вчених, які мають науковий ступінь за однією із спеціальностей, що відповідають науковому профілю видання згідно з пунктом 5 цього Порядку. Кожен з цих фахівців, включаючи головного редактора видання, повинен мати не менше трьох публікацій за останні п’ять років або не менше семи публікацій (статті, монографії, розділи монографій, що відповідають науковому профілю видання) за останні п’ять років, у тому числі не менше однієї за останні три роки, опублікованих щонайменше у двох різних виданнях, включених до Web of Science Core Collection та/або Scopus, або мати монографії чи розділи монографій, видані міжнародними видавництвами, що належать до категорій «A», «B» або «C» за класифікацією Research School for Socio-Economic and Natural Sciences of the Environment (SENSE).

У складі редакційної колегії має бути не менше трьох вчених, що працюють за основним місцем роботи в українських наукових установах або закладах вищої освіти, і щонайменше - один науковець, що працює за основним місцем роботи в закордонній науковій установі або закладі вищої освіти. Для включення вченого до складу редакційної колегії потрібна його письмова згоди. Вчений може входити до складу не більше як трьох редакційних колегій видань, включених до Переліку;

FIGURE 2. (cont’d). (C) Cropped copy of 3rd page of the Order of the Ministry of Education and Science of Ukraine. (Fig 2 continued on next page.)
8) включення до профільних міжнародних наукометричних баз даних, рекомендованих МОН.

7. Для включення періодичного наукового фахового видання до Переліку (категорії «А» та «Б») до МОН подаються такі документи:

1) клопотання засновника (співзасновників) наукового фахового видання про включення до Переліку на офіційному бланку, засвідчене підписанням керівника;

2) заповнений бланк заяви на включення наукового видання до Переліку наукових фахових видань України (додаток) на паперовому та електронному носіях;

3) ксерокопія свідоцтва про державну реєстрацію друкованого засобу масової інформації (для друкованих періодичних видань) або витяг з наказу засновника про утворення електронного наукового періодичного видання;

4) документ про здійснення обов’язкового розсилання періодичного видання відповідно до додатка до постанови Кабінету Міністрів України від 10 травня 2002 року № 608 «Про порядок доставлення обов’язкових примірників документів»;

5) два останні номери видання по одному примірнику з копіями рецензій на опубліковані матеріали (з забезпеченням анонімності особи рецензента).

8. Подані документи розглядаються відповідною експертною радою з питань проведення експертизи дисертаційних робіт МОН відповідно до підпункту 4 пункту 8 Положення про експертну раду з питань проведення експертизи дисертаційних робіт Міністерства освіти і науки, молоді та спорту України, затвердженого наказом Міністерства освіти і науки, молоді та спорту України від 14 вересня 2011 року № 1058, зареєстрованого в Міністерстві юстиції України 10 жовтня 2011 року за № 1167/19905 (далі - Положення). За наявності позитивного висновку експертної ради з питань проведення експертизи дисертаційних робіт, затвердженого відповідно до Положення, матеріали подаються на розгляд апеляційної колегії МОН для прийняття рішення.

9. Наказ про включення наукового видання до Переліку МОН припиняється на офіційному web-сайті. У разі відмови про включення до Переліку або передчасного виключення видання з Переліку МОН офіційним листом інформує засновника (співзасновників) про причини відмови щодо включення або виключення.

10. Рішення МОН про відмову у включенні наукового видання до Переліку може бути оскаржено протягом місяця з дня отримання засновником (співзасновниками) листа з підставами про відмову шляхом подання до МОН апеляційної заяви або до суду в порядку, передбаченому законодавством.

11. Під час включення наукового видання до Переліку йому присвоюється відповідна категорія, яку разом з датою включення до Переліку необхідно вказувати у вихідних відомостях видання:

1) категорія «А» присвоюється науковим фаховим виданням, включеним до міжнародних наукометричних баз даних Web of Science Core Collection та/або Scopus;

2) категорія «Б» присвоюється іншим науковим фаховим виданням, які відповідають вимогам підпунктів 1–8 пункту 6 цього Порядку;

3) категорія «В» присвоюється всім науковим фаховим виданням, включеним до Переліку на день затвердження цього Порядку наказами МОН, а також може присвоюватись виданням, які були включені з категорії «А» або категорії «Б» на два роки.

Видання категорії «В», яке протягом двох років не отримало права на присвоєння категорії «А» чи категорії «Б», виключається з Переліку без права поновлення.

12. У разі перерегистрації друкованого видання зі зміною свідоцтва про державну реєстрацію друкованого засобу масової інформації або змін в електронному виданні засновник (співзасновник) має/єдеться впродовж одного місяця подати до МОН клопотання щодо внесення змін до Переліку та ксерокопію нового свідоцтва про державну реєстрацію друкованого засобу.
masovoi informatsii abo vitiat z zakazu zasnovnika pro zmieni v elektornomu naukovomu periodichному виданн.

13. Vidannya, yake otrzymalo status fahovogo iz vyznachenniam pivenoi kategorii, obolv'jako pidiya monitoryngu MON щодо dotrимannya nim vymog цього Порядку. Za rezultatami monitoryngu vidannya може zalishititsya u vidnovidni kategorii, buoti переведенim do inshoi kategorii abo viklychenim z Pereliku, pro yu MON informuе zasnovnika (spivzасновникiв) naukovoho vidannya ta vyisvitlue yu informatsii на офiцiйному web-sajti.

14. Naukove fahove vidannya viklychayetsya z Pereliku abo переводиться до nizhinoi kategorii za rizheniam MON u raz vyvianienia poruschen vymog, передбачених одним iz pidpunktiv 1-8 (vinklychenia z kategorii «B»), abo pidpunktiv 1-5 (vinklychenia z kategorii «B») punktu 6 цього Порядку. U raz viklychenня naukovoho vidannya z Pereliku zasnovnik (spivzасновники) може(уть) podavati naye klopotannya pias vyprovadzenia zauvazhen MON ne ranentshe njikh через rik za dni priiniatia takogo rizhennia.

U razu poverhnotnogo vyvianienia ych poruschen vidannya viklychayetsya z Pereliku bez prava ponovalennia.

Pidstavami dla viklychenia vidannya z Pereliku za rizheniam MON takож є:

- porushenia pri opublikuvannia vidannya redaktsiiu, avtomrariami publikatsii, reцензентами principiiv akademichnoi dobrychesti, передбачених законами України;
- systematichni publikatsii materialiv, які ні містять нових наукових результатів, i vyhodnokai nepiustia informatsii pro te, yu oni є ogladovymi chi naukovo-methodichnymi.

15. Gолова та члени redaktsiinoi kollegii є vidpovidalnymi za organiatsiiu reцензuvannia statii та dotrимannya akademichnoi dobrychesti.

16. Pri vinklychenii vidannya kategorii «A» z naukometrichnih baz Web of Science Core Collection та/або Scopus воно набуває statusu vidannya kategorii «B». Pri vyvianini pidstav dla viklychenia vidannya z kategorii «B» воно vinklychayetsya z Pereliku abo набуває statusu vidannya kategorii «B». U yih vypadkah vidannya pldya перевiри на наявність pidstav для viklychenia yihого з Pereliku відповідно do punktu 14 цього Порядку.

Директор департаменту
атестацii kadriv vishoi
kvalifkatsii та lizenzuvannya

А.Г. Шевцов

FIGURE 2. (cont’d). (E) Cropped copy of 5th page of the Order of the Ministry of Education and Science of Ukraine. Important items are indicated by red lines.

Acknowledgments

The author would like to thank Ievgen I. Fesenko (Managing Editor) for assistance in editing this Editorial.

References

Consulting Editor of the highly prestigious Journal Oral and Maxillofacial Surgery Clinics of North America. Textbooks: Local & Regional Flaps in Head & Neck Reconstruction: A Practical Approach (Fernandes) – published in 2014; Oral, Head & Neck Oncology & Reconstructive Surgery (Bell, Fernandes, Andersen) – published in 2017. Co-author in the cutting-edge articles: Outcomes of total or near-total lip reconstruction with microvascular tissue transfer; Margin analysis: sarcoma of the head and neck; The cervicofacial flap in cheek reconstruction: a guide for flap design; Alternative approach in mandibular reconstruction for benign disease [3-6]. The list goes on. He don't stop to relax. He continue to do that again, and again, and again... To move a surgery forward.

References

Reconstruction of Severely Atrophic Mandible by Installing Dental Implants Using the Modified “Tent Pole” Technique: Case Report*

Rodrigo Tavares de Sá1*, Lincoln Lara Cardoso1, Italo Cordeiro de Toledo2, Luis Gustavo Jaime Paiva2, Guilherme Romano Scartezini3, and Giovanni Gasperini3

1 DDS, MS; PhD; Department of Oral and Maxillofacial Surgery, Clinical Hospital, Federal University of Goiás, Goiás, Brazil
2 DDS, MS; PhD; Department of Oral and Maxillofacial Surgery, Emergency Hospital of Aparecida de Goiânia, Goiás, Brazil
3 DDS, MS; PhD; Department of Oral and Maxillofacial Surgery, Clinical Hospital, Federal University of Goiás, Goiás, Brazil

A B O U T A R T I C L E

Article history:
Paper received 21 August 2018
Accepted 05 September 2018
Available online 30 September 2018

Keywords:
Mandibular reconstruction
Dental implants
"Tentpole" technique
"Tent pole" technique
Autogenous iliac crest graft
Platelet-rich plasma (PRP)

A B S T R A C T

Summary.
Patients who use full dental prostheses for long periods of time usually experience bone resorption in the alveolar process and in keratinized mucosa. This can cause instability, low prosthetic retention, and subsequent loss of function. Treating a patient with a severely atrophic mandible is quite challenging due to the low bone height and thickness, potentially impairing rehabilitation, aesthetics, and functional recovery. Several techniques are used to reconstruct major vertical defects for the installation of dental implants. Among these is the "tent pole" technique, which features low morbidity and generally produces good results in the form of increased height of the alveolar ridge bone. Herein we describes a patient with a severely atrophic mandible, reconstructed using a plate and dental implants. We employed a modified "tent pole" technique using an autogenous graft of the iliac crest and without use of platelet-rich plasma concentrate. Our results indicate that the modified tent pole technique using the iliac crest graft, and without use of platelet-rich plasma, is a safe and effective method for achieving mandibular reconstruction while restoring function, aesthetics, and the patients’ quality of life.

ABOUT ARTICLE

Article history:
Paper received 21 August 2018
Accepted 05 September 2018
Available online 30 September 2018

Keywords:
Mandibular reconstruction
Dental implants
"Tentpole" technique
"Tent pole" technique
Autogenous iliac crest graft
Platelet-rich plasma (PRP)

A B S T R A C T

Summary.
Patients who use full dental prostheses for long periods of time usually experience bone resorption in the alveolar process and in keratinized mucosa. This can cause instability, low prosthetic retention, and subsequent loss of function. Treating a patient with a severely atrophic mandible is quite challenging due to the low bone height and thickness, potentially impairing rehabilitation, aesthetics, and functional recovery. Several techniques are used to reconstruct major vertical defects for the installation of dental implants. Among these is the "tent pole" technique, which features low morbidity and generally produces good results in the form of increased height of the alveolar ridge bone. Herein we describes a patient with a severely atrophic mandible, reconstructed using a plate and dental implants. We employed a modified "tent pole" technique using an autogenous graft of the iliac crest and without use of platelet-rich plasma concentrate. Our results indicate that the modified tent pole technique using the iliac crest graft, and without use of platelet-rich plasma, is a safe and effective method for achieving mandibular reconstruction while restoring function, aesthetics, and the patients’ quality of life.

Introduction

In edentulous patients, prolonged use of removable total dental prostheses may cause reabsorption of the alveolar bone and consequent reduction of the keratinized mucosa. These processes can result in poor prosthetic retention and loss of function. Prosthetic maladjustment and constant trauma to the mucosa may produce pain as well as functional and aesthetic limitations that affect patients’ quality of life [1, 2].

Treatment for a severely atrophic mandible is a major challenge for both the prosthodontist and the maxillofacial surgeon due to the minimal amount of alveolar ridge bone that is generally available. Several techniques have been described that can increase osseous volume, allowing the installation of dental implants [3], however, these techniques are also associated with complications such as extensive osseous reabsorption, pathological fractures, osseous graft failure, recurrent infections, fistulas, chronic pain, and sensory disorders [4].

In 2002, Marx et al [2] described the “tent pole” technique (synonym: tentpole technique) for tissue matrix expansion. This involves installation of 4 to 6 dental implants in patients whose mandibles have less than 6 mm of bone thickness, classified as Cawood-Howell type V1 [1]. Using submandibular access, an autogenous iliac crest graft is used with platelet-rich plasma (PRP) concentrate and dental implants. The tent pole increase can reportedly increase bone height by as much as 10.2 mm [2].

PRP with bone grafts were successfully used in several studies in animals and humans [5-11]. Still other authors have reported successful use of the technique even without PRP [4].

Here in we report a clinical case involving reconstruction of a severely atrophic edentulous mandible through the fixation of a 2.4 mm reconstructive plate and use of a modified tent pole technique without use of PRP [12-16].
Clinical Case Report

A 71-year-old male patient, diagnosed with leukoderma, presented with complaints of impaired mastication, instability, and an inability to use his lower removable total prosthesis. The patient did not present with any systemic comorbidities. Clinical examination revealed edentulous arches, an atrophic mandible, a small amount of keratinized mucosa, and chronic oral mucosa trauma.

Panoramic jaw radiography and cone beam computed tomography revealed low mandibular bone availability, designated class V according to the classification system proposed by Cawood and Howell [1]. This rendered the patient’s mandible unsuitable for rehabilitation using only integrated bone dental implants (Fig 1).

The procedure was performed under general anesthesia. Marx et al [2], protocol involving submandibular access with exposure of the mandible and installation of 4 to 6 implants in the anterior region of mandible, between the two mental foramens.

One 2.4 mm reconstructive plate (OsteoMed, Addison, Texas, USA) was installed, followed by mandibular body to body to support the mandibular masticatory load. Two 11 mm implants (Neodent, Curitiba, Paraná, Brazil), with 3.0 mm platforms, were centrally mounted followed by another two (Neodent, Curitiba, Paraná, Brazil), more distal 13 mm implants with 3.3 mm platforms (Fig 2A). We then removed the right anterior iliac crest graft.

A bone crusher was used to form small bone particles to facilitate adaptation fitting strategically around each dental implant. Both particulate graft and dental implants were covered with two collagen membranes (Geistlich Bio-Gide, Switzerland), the platelet-rich plasma was not use (Fig 2B). Thus surgical approach was synthesized with 4-0 vycril sutures for internal layers and 5-0 nylon sutures for skin. During the period of implant osseointegration and bone graft incorporation, the patient was advised not to use his lower total prosthesis and only consume soft consistency food throughout the postoperative period.

The osseointegration and bone graft incorporation processes took seven months to complete. Following reopening of the implants under local anesthesia, an alveolar crest incision was made to the mental foramen, the mucoperiosteum was then detached and the implant lid screws were removed without any difficulties. Transmucosal cicatrizers were finally installed and the patient was referred for rehabilitation with prosthesis under the implant. At the time of this report, the patient had experienced no adverse effects over the 14 month postoperative period (Fig 3).

Discussion

Although the last few decades have seen great advances in dentistry, the rehabilitation of atrophic mandibles is quite delicate, requiring careful manipulation of remaining tissues in order to improve hard tissue availability. The autogenous bone graft is considered a gold standard technique and holds the advantage of increasing mandibular bone volume, establishing a better relationship between the maxilla and mandible, improving residual alveolar ridge shape, and producing great functional and aesthetic gains following prosthetic treatment [4, 17].

FIGURE 1. Panoramic preservative radiograph; note the severe bone reabsorption, classified as type VI, according to Cawood and Howell [1].
FIGURE 2. A – a 2.4 mm reconstruction plate was installed to the mandibular body, followed by installation of two central implants: an 11 mm implant with 3.0 mm platforms and two distal 13 mm implants with 3.3 mm platforms. B – Adaptation of an autogenous graft (asterisk) of the anterior iliac crest, with two collagen membranes (arrows) covering the graft.
The tent pole technique uses an autogenous iliac crest graft, followed by immediate installation of dental implants. This promotes greater hard tissue availability and soft tissue gains, produces efficient surgical results, and is associated with minimal morbidity [2].

The advantages of this procedure are stable height gains from osseous tissue, a lower risk of mandible fracture, and a successful prosthetic retention. Postoperative infections, mental nerve paresthesias, donor site deformities, and transoperative mandible fractures are complications associated with this procedure.

Ellis and Prince [18] and Eyrich et al [20] reported that installation of a rigid fixation plate associated with a bone graft and followed by the immediate installation of dental implants produced more stable results, compared to the patients who only received bone grafts. This technique may help prevent mandibular fractures from occurring during the intraoperative period, especially when the mandible is less than 10 mm in height and therefore classified as severely atrophic [1, 5].

Marx et al [2] described installation of 4 to 6 implants which were covered with an iliac crest graft and PRP; however, Korpi et al [4] described a series of 22 patients successfully treated with iliac crest grafts and without PRP. Hence, questions surrounding the use of PRP as a component of this protocol remain unresolved.

The tent pole technique is a safe and effective alternative method for reconstruction of severely atrophic mandibles, even without the addition of PRP. This method can help solve functional and aesthetic complaints and improve the patient’s quality of life. Because the use of PRP remains uncertain in the literature, additional double blind and randomized clinical trials are needed to define the role of PRP in these reconstructions.

Conflict of Interest

The authors declare no conflict of interest.

Role of the Authors and Co-authors

Rodrigo Tavares de Sá (concept and design of the paper and writing)
Lincoln Lara Cardoso (material collection and writing)
Italo Cordeiro de Toledo (material collection and writing)
Luis Gustavo Jaime Paiva (material collection and writing)
Guilherme Romano Scartezini (material collection and writing)
Giovanni Gasperini (material collection and editing)

Ethical Approval

None.

Term of Consent

Written patient consent was obtained from parents to publish the clinical photographs.

Fundings

No funding was received for this study.
MANDIBLE RECONSTRUCTION USING MODIFIED “TENT POLE” TECHNIQUE

References

None.

Acknowledgments

None.


https://doi.org/10.1016/j.joms.2018.03.117

https://doi.org/10.1016/j.joms.2018.03.03.

https://doi.org/10.1016/j.joms.2018.03.117

https://doi.org/10.1016/j.joms.2018.03.03.
Linkows’ Blade-Vent Implants Continue to Work After Twenty-Nine Years: Case Report*

Zinaida Y. Zhehulovych1, Ievgen I. Fesenko2, and Nadim S. Al-Makhamid3

1 Assoc Prof, Department of Dentistry, Institute of Postgraduate Education, Bogomolets National Medical University, Kyiv, Ukraine (ScD, Assoc Prof)
2 Assoc Prof, Department of Oral and Maxillofacial Surgery, Private Higher Educational Establishment “Kyiv Medical University”, Kyiv, Ukraine (PhD, Center of Maxillofacial Surgery, Kyiv Regional Clinical Hospital (place of work at moment of the material collection)
3 1st yr intern, Stomatology Institute, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine

© 2018 OMF Publishing, LLC. All rights reserved.

ABOUT ARTICLE

Article history:
Paper received 21 August 2018
Accepted 15 September 2018
Available online 30 September 2018

Keywords:
Dental implants
Blade-vent implants
Osseointegration
Fixed partial denture (FPD)
Tooth-implant supported fixed partial denture
Abutment teeth

ABSTRACT

Symmary.
We report a case of two osseointegrated Linkows’ blade-vent implants [1] supported fixed partial dentures that still osseointegrated at the mandible of 54-year-old patient during last twenty-nine years. The purpose of the report is to compare the bone condition around the blade-vent implants, condition of the fixed dentures, and two abutment teeth. Benefits and disadvantages of Linkows’ blade-vent implants are also highlighted [24].

Introduction

Endosseous blade-vent implants (related names: blade implants, Linkow-type blade implants, Linkow-type blade vent implants) were introduced by American dentist and pioneer in the field of oral implantology Leonard Linkow in 1968 [1, 2]. First 2 year follow-up results were presented by him in 1970 [3]. The whole next five decades is a period that shows a transition from wide blade-vent and subperiosteal implants usage to root-form and zygomatic implants usage not only into jaws but also into flap-reconstructed mandible/maxilla [4, 5]. A lot of publications show that, despite of disadvantages, blade-vent implants continue to work in the long time follow-up period [6-20]. One of them is Pasqualini and Pasqualini (2003) publication, who reported a success rate of 91% at 10 years for 386 blade implants placed between 1971 and 2009 [2, 7]. Risks and benefits of connecting an implant and natural tooth were precisely described by Brägger et al (2001), Cordaro et al (2005), Nickenig et al (2006), and Davis et al (2014) [21-24]. Our case represents a unique comparison of long-term usage of two tooth-blade-vent-implant supported fixed partial dentures with different conditions of denture-supported teeth (endodontically treated vs non-treated).

Case Presentation

A healthy 54-year-old lady referred to the Center of Maxillofacial Surgery for a one month history of movement of one of the fixed partial dentures. Out-office oral examination revealed a non-significant mobility of an anterior part of tooth-implant fixed partial denture in area of tooth 3.4 (Figs 1 and 2B) and signs of gingival inflammation in the area of contact of the movable part of the denture near root of the tooth 3.4. Mobility of the denture was caused by the destruction of crown of the abutment teeth 3.4 by caries. The tooth-implant fixed partial denture on the opposite site shows no mobility and symptoms of gingival inflammation.

A panoramic radiography (Figs 1, 2) shows two blade-vent implants with the tooth-implant supported fixed partial dentures. A good bone level at the alveolar ridge in areas of inserted blade-vent implants was noted. According to patient medical history the two blade-vent implants (there was no precise data about manufacturer; implants material is presumably titanium, taking into account the production capacity in the late 1980s and the longevity of these two implants) placement and prosthetic work were performed in 1986 at Department of Prosthetic Dentistry, Bogomolets National Medical University (Kyiv, Ukraine). Endodontic treatment of the tooth 4.4 was performed simultaneously with blade implants placement. At maxilla
FIGURE 1. A panoramic radiograph of 54-year-old lady after 29 years of the blade-vent implants (arrows) placement. Notes the mobility (arrowhead indicates direction of mobility) of fixed bridge (cement fixation) on the tooth 3.4. Oral examination revealed destruction of the crown part of tooth 3.4 with caries to the level of tooth neck. Radiograph shows no radiopaque filling material inside a root canal of tooth 3.4. No crestal bone resorption or peri-implant radiolucencies are present.

FIGURE 2. A cropped and zoomed panoramic radiograph of the same patient. The teeth are indicated by numbers: (A) Tooth-implant fixed partial denture on the right side. Denture is fixed at endodontically treated tooth 4.4. (B) Tooth-implant fixed partial denture on the left side. Denture is fixed at non-treated tooth 3.4.

a patient used a fully removable denture during the whole period of dental implants function at the mandible. The condition upon oral examination and panoramic radiography clearly demonstrate us the need of tooth 3.4 treatment with possibility to use it as abutment tooth further in new tooth-implant supported fixed partial denture.

Discussion

Naert et al (2001) [25] in their study of 339 implants fixed to 313 abutment teeth, shows that complications with the implant-tooth group included: periapical lesions (3.5%), tooth fracture (0.6%), extraction (decay or periodontal disease) (1%), intrusion (3.4%), and cement failure (8%). Davis et al (2014) [24] argued about the next advantages of a tooth-implant supported fixed partial dentures: 1) increased tactile perception; 2) greater chewing comfort and efficiency; 3) avoidance of vital structures; 4) reduced cost; 5) reduced need for advanced graft; 6) improved patient acceptance.
Thus, upon the planning of the tooth-implant supported fixed partial dentures the next risks [24] cannot be ignored: 1) intrusion of natural tooth; 2) biomechanical complications: fixture-abutment failure, loss of retention, screw loosening/implant fracture (implant, especially risk is high in the neck of blade implants [26], cement failure (implant/tooth), fracture (tooth), caries (tooth), crown fracture; 3) loss of natural tooth: endodontic involvement, fracture, caries, periodontal disease; 4) peri-implantitis.

Conclusion

The twenty-nine years of two blade-vent implants function in implant-tooth fixed dentures confirms: 1) a possibility of blade implants to perform function; 2) to be a long-term period successfully osseointegrated; 3) to have insignificant bone resorption around the implants, showing no alveolar ridge atrophy; 4) a tooth-blade-vent-implant supported fixed partial denture can long-term exist in case of healthy/perfect endodontically treated abutment teeth.

And we are completely supporting an opinion of Davis et al (2014) [24] that for the sake of increasing predictability, cases for combination tooth-implant supported FPDs should include ideal proposed implant location, healthy natural/endodontically treated abutment teeth, and excellent patient factors such as occlusion, oral hygiene, and motivation.

Conflict of Interest

The authors declare no conflict of interest.

Role of the Authors and Co-authors

Zinaida Y. Zhehulovych (editing)
Ivgen I. Fezenko (material collection, concept of a paper, and editing)
Nadim S. Al-Makhamid (material collection and writing)

Ethical Approval

No needed.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgments

The authors are grateful to Sergii I. Khrulenko (x-ray laboratory assistant; Kyiv Regional Clinical Hospital, Kyiv, Ukraine) for high quality panoramic radiography (images of Fig 1, 2).

References


Correlation and Accuracy of Labial Minor Salivary Gland Biopsy in the Establishment of Diagnosis in Patients with Suspected Sjögren’s Syndrome

Evangelos G. Kilipiris1,*, Katarina Machalekova3, Georgia Fountoulaki1, Kareen Andrade4, Nikolaos Mantziaris5, and Peter Stanko6

ABOUT ARTICLE

Article history:
Paper received 04 June 2018
Accepted 25 June 2018
Available online 30 September 2018

Keywords:
Sjögren syndrome
Salivary disease
Parotid swelling
Keratoconjunctivitis sicca
Dry mouth
Dry eyes
Xerostomia
Labial minor salivary glands
Focal lymphocytic infiltration
Focus score

ABSTRACT

Purpose.
The goal of this paper is to find out the correlation, and evaluate the accuracy of labial minor salivary gland biopsy as a diagnostic tool in the multidisciplinary management of patients with Sjögren's syndrome.

Patients and Methods.
Thirty seven patients referred to our outpatient office between January 2016 and December 2017 from a rheumatologist for biopsy examination, as part of the complex diagnostic plan for suspected Sjögren syndrome were included in the current study. Each specimen was examined histomorphometrically by the pathologist to calculate the focus score describing the degree of salivary gland inflammatory infiltration.

Results.
From the total number of patients, 25 presented with an established Sjögren syndrome diagnosis by fulfilling the revised American-European criteria. From those 15 had a positive lip biopsy. The rest 10 patients from the total group who were diagnosed with Sjögren syndrome based on the same criteria had a negative lip biopsy.

Conclusion.
The labial minor salivary gland biopsy is a valuable diagnostic tool to establish the diagnosis of Sjögren syndrome. However, a positive biopsy result must always be correlated with all the other diagnostic criteria to prove the exact diagnosis.

Classically, two types have been described: i) the primary Sjögren syndrome characterized by a combination of keratoconjunctivitis sicca and xerostomia and ii) the secondary Sjögren syndrome which is defined by a triad of keratoconjunctivitis sicca, xerostomia and an autoimmune disease, usually rheumatoid arthritis, but also systemic lupus erythematosus or scleroderma.

Nine out of ten Sjögren syndrome patients are women, around the fifth decade of life [2]. The spectrum of the disease extends from an organ-specific autoimmune disease to a systemic process with diverse extraglandular manifestations. The hallmark symptoms of Sjögren syndrome are dry mouth and dry eyes. However, clinical features may also include other head and neck manifestations involving the nose, ears, throat, thyroid...
gland, and systemic symptoms such as neurologic, pulmonary, gastrointestinal and hematologic [3].

Sjögren syndrome often is undiagnosed or misdiagnosed. The symptoms of Sjögren syndrome may mimic those of menopause, drug side effects, or medical conditions such as lupus, rheumatoid arthritis, fibromyalgia, chronic fatigue syndrome and multiple sclerosis. Because all symptoms are not always present at the same time and because Sjögren syndrome can involve several body systems, physicians sometimes treat each symptom individually and do not recognize that a systemic disease is present [4]. Eight to ten years are generally required for the disorder to progress from initial symptoms to the development of the syndrome. While some patients experience mild discomfort, others suffer debilitating symptoms that greatly impair their functioning.

Sjögren syndrome is treatable. Early diagnosis and consequently proper treatment may prevent serious complications and greatly improve the quality of life for these patients [5]. However, patients with Sjögren syndrome are generally picked up at a late stage in their disease, after the salivary and lacrimal glands are already destroyed, because they are asymptomatic until that time. Unfortunately, at this point only symptomatic treatment can be offered.

Although rheumatologists have primary responsibility for managing Sjögren syndrome, patients suspected to have Sjögren syndrome often are referred to an Oral and Maxillofacial surgeon for evaluation and biopsy to rule out the disease.

A Sjögren syndrome work-up can include various objective tests, such as Schirmer test, sialometry, injection sialography and scintigraphy that add little to the diagnosis, but provide information about the degree of ductal and acinar destruction [6]. The same information can be obtained from a CT or MRI scan, which will often show internal hypodense areas indicative of ductal ectasia and salivary pooling.

A more focused work-up should seek to establish histopathological confirmation. For this purpose, oral labial minor salivary gland biopsy has been traditionally considered the most valuable diagnostic tool for the diagnosis of Sjögren syndrome, especially in patients who present with inconclusive clinical findings [7]. With all this background, the aim of this study is to discover the accuracy and effectiveness of this diagnostic procedure in the establishment of diagnosis in patients with suspected Sjögren syndrome.

Materials and methods

Between January 2016 and December 2017, 37 patients were referred to the Outpatients Office of the Department of Oral and Maxillofacial Surgery, St. Elizabeth Oncologic Clinic and Comenius University in Bratislava, Slovakia with suspected Sjögren syndrome.

Criteria for patient selection to this study were: i) patients sent from rheumatologists for further examination of suspected Sjögren syndrome and ii) patients with at least one sicca symptom (either xerostomia or xerophthalmia) at the time of presentation. Patients with other established systemic diseases with symptoms similar to Sjögren syndrome and xerostomia as a result of medicaments, radiotherapy to the head and neck region and chemotherapy were excluded from the study.

A complete history and physical evaluation were performed. In addition to lip biopsy, the following diagnostic tools were employed: anti-SSA/Ro or anti-SSB/La antibodies, Schirmer test, ultrasonography and scintigraphy.

The biopsy specimens were taken from beneath a clinically normal mucosa of the lower lip between the midline and commissure, and 5 to 10 minor salivary glands were removed for examination. Local infiltration with anesthetic containing vasoconstrictor was applied, followed by a single incision of 1.5-2 cm vertically to just penetrate epithelium. The minor salivary glands were then removed by blunt dissection, while avoiding sensory nerves (Fig 1A, B). The fragments of minor salivary glands were sent for histopathological examination in the Department of Pathology of St. Elizabeth Oncologic Clinic and processed completely according to Sjögren syndrome focus score grading the degree of salivary gland inflammatory infiltration. A focus score of 1 or greater was considered supportive of the diagnosis of Sjögren syndrome. Long term follow up was introduced with assessment every 3 months.

Result

Of the 37 patients meeting the selection criteria, the average age at the time of presentation was 51 years. The oldest patient was 78 years and the youngest 6 years at the time of first examination. Female patients were 31 while the male patients were 6. During physical examination, patients presented with a wide range of clinical findings including xerostomia, xerophthalmia, difficulty in swallowing, inability to speak continuously for longer than several minutes, altered taste, fissured tongue, red and tender oral mucosa, decreased vision, asymmetric and painless enlargement of major salivary glands.

In the present study, evaluation of the accuracy of minor salivary gland lip biopsy in the support of Sjögren syndrome diagnosis was performed by comparing the biopsy result (either positive or negative) and the criteria for classification of the disease. From the 37 patients included in the study, 25 concluded with an established Sjögren syndrome diagnosis. From those, 15 (60%) had a positive lip biopsy and all of them were confirmed to fulfill the revised American–European criteria establishing the diagnosis of the syndrome. A number of 10 patients from the total group (27%) were diagnosed with Sjögren syndrome, based on the above criteria despite
FIGURE 1. (A) Exposure of minor salivary gland (arrow) fragment after a small vertical incision on the labial mucosa. (B) Suturing of the wound after removal of the fragments.
of presenting a negative minor salivary gland lip biopsy. All of the patients, 12 in the number, whose diagnostic criteria didn’t support the diagnosis of Sjögren syndrome, presented with a negative lip biopsy (Fig 2). Among the 25 patients diagnosed with the disease, 7 were observed with the criteria of secondary Sjögren syndrome, with the most common established connective tissue disorder being rheumatoid arthritis in 4 patients (Chart 1).

Salivary gland scintigraphy was additionally performed in 12 patients of the study group who concluded with established Sjögren syndrome. The construction of time-activity curves presented reduced major salivary gland function. In 8 patients the radionuclide uptake from the blood to the major salivary glands was normal, but the excretion into the oral cavity was significantly decreased. The rest 4 patients who appeared with increased salivary dysfunction, both uptake and excretion of the radionuclide was diminished. Moreover, these patients presented with the highest focus score level. Characteristic histopathological changes of positive specimens included loss of acinar cells, a relative preservation of ductal structures, and the presence of an intense, focal periductal/vascular mononuclear cell infiltrate (Fig 2).
FIGURE 3. (A) Image without notations. Two minor salivary glands exhibiting a focal lymphocytic pattern of inflammatory cell infiltration (hematoxylin and eosin stain, × 100). (B) Image with notations. Two minor salivary glands (indicated with white lines and arrows) exhibiting a focal lymphocytic pattern of inflammatory cell infiltration (the areas with biggest infiltration are indicated with purple lines and words lymphocytic infiltration).
MINOR SALIVARY GLAND BIOPSY IN SJÖGREN’S SYNDROM PATIENTS

Discussion

The current standards for diagnosis of Sjögren syndrome are described by the revised American-European criteria (Table 1). The diagnosis of primary Sjögren syndrome requires 4 out of the 6 criteria, involving either a positive lip biopsy or positive anti-SSA/Ro or anti-SSB/La. Secondary Sjögren syndrome requires an established connective tissue disease and at least one sicca symptom plus 2 out of 3 objective tests for either xeropthalmia or xerostomia. It should be noted that Sjögren syndrome can also be diagnosed in the absence of sicca symptoms if 3 out of 4 objective tests are positive (Table 1).

<table>
<thead>
<tr>
<th>Ocular Symptoms (1 of 3)</th>
<th>Oral Symptoms (1 of 3)</th>
<th>Ocular Tests (1 of 2)</th>
<th>Oral Tests (1 of 3)</th>
<th>Positive Lip Biopsy</th>
<th>Positive Anti-SSA and/or SSB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dry eyes for longer than 3 months</td>
<td>Dry mouth for longer than 3 months</td>
<td>Unanesthetized Schirmer’s test (less than 5mm in 5 minutes)</td>
<td>Unstimulated salivary flow (less than 0.1 mL/min)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensation of a foreign body in the eye</td>
<td>Swollen salivary glands</td>
<td>Vital dye staining</td>
<td>Abnormal parotid sialography</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use of artificial tears more than 3 times a day</td>
<td>Need liquids to swallow</td>
<td></td>
<td>Abnormal salivary scintigraphy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Salivary glands involved by this condition show a focal lymphocytic pattern of infiltration, in which there are multiple interstitial aggregate foci of inflammatory cells (Fig 4). An aggregate focus is defined as a collection of greater than 50 inflammatory cells. The focal lymphocytic infiltrate, including focal aggregates of 50 or more lymphocytes, defined as a focus, that are adjacent to normal appearing acini and the consistent presence of these foci in all or most of the glands in the specimen is the characteristic microscopic feature of Sjögren’s syndrome in the minor salivary glands. These histopathological changes represent the hallmark of this disorder [8].

The infiltrate should consist predominantly of lymphocytes (Fig 5). The study showed that the prevalent cells in the minor labial salivary gland infiltrate were those bearing the T-helper phenotype (CD4+). These T cells also express the adhesion molecule LFA-1 (lymphocyte function associated molecule) and other T cell markers, such as CD2 and LFA-3, which mediate an antigen independent interaction and are up-regulated after lymphocytic activation. B cells constitute approximately 20% of the total infiltrating population, while NK cells are rarely observed. There may be admixed plasma cells and histiocytes, but these cells should not comprise a significant portion of the infiltrate. Granulomatous inflammation should not be present. Uncommonly, epimyoepithelial islands may occur in minor salivary glands of patients affected by Sjögren syndrome.

The Sjögren syndrome focus score is a semiquantitative method of grading the degree of salivary gland inflammatory infiltration [9]. Histomorphometric analysis is utilized by the pathologist to quantitate the area of salivary gland parenchyma in square millimeters, by counting the number of lymphocytic aggregates. The focus score represents the number of lymphocytic aggregates per 4 square millimeters, and therefore an absolute minimum of 4 square millimeters of salivary gland tissue is required to calculate the focus score. A focus score of 1 or greater is considered supportive the diagnosis of Sjögren syndrome. The focus score can range from 0 to 12, with a focus score of 12 representing diffuse glandular effacement by the lymphocytic infiltrate and a score 0 referring to the absence of these cells. The presence of a dense effacing infiltrate should raise concern for possible progression to lymphoma.

The focus score has been validated as a histological index of severity of the salivary gland involvement in Sjögren syndrome [10]. A series of studies have correlated the presence of high focus scores with indices of local or systemic disease activity. The presence of a higher focus score has been found to correlate with acinar damage, presence of anti-SSA/B serology (12 times higher among those with focus score >1 than among those with focus score <1), and the presence of specific extraglandular features such as Raynaud’s phenomenon, vasculitis, lymph node or spleen enlargement and leucopenia. A focus score >1 has also been found to correlate with positive RF serology, high ANA titers and IgG concentrations, the presence of keratoconjunctivitis sicca and low unstimulated but not stimulated salivary flow rates. More recently, it has been established that a high focus score (>3) has a significant predictive value for the development of non-Hodgkin B cell lymphoma [11].

In our study, the focus score in the group of the examined patients who presented with a positive lip minor salivary gland biopsy, was extended from 1 to
FIGURE 4. (A) Image without notations. Minor salivary gland with multiple lymphocytic aggregate foci (hematoxylin and eosin stain, × 200). (B) Image with notations. Minor salivary gland with multiple lymphocytic aggregate foci (the lymphocytic aggregate foci are indicated with purple-white lines and words lymphocytic aggregate foci).
FIGURE 5. (A) Image without notations. Section showing a dense aggregate of lymphocytes with adjacent intact salivary gland parenchyma (hematoxylin and eosin stain, × 400). (B) The same image with notations. Section showing a dense aggregate of lymphocytes (the lymphocytes are indicated with purple-white lines and words lymphocytes) with adjacent intact salivary gland parenchyma.
6.42 with the highest values seen in patients with Sjögren syndrome without associated connective tissue disease (primary Sjögren syndrome). It was also pointed out that the focus score cannot separate early from late disease as chronicity of symptoms and focus score did not show a relationship.

Minor salivary gland lip biopsy results report a useful diagnostic value in Sjögren syndrome. They should be carefully addressed in the overall diagnostic procedure due to inconsistencies of sensitivity and specificity. Whilst the focus score has been proven as a functional diagnostic and prognostic tool, it presents obvious limitations.

First, the stability of the focus score in repeated biopsies over a long period of time is not fully established. In a recent study, surprisingly, in 12% of the cases the second evaluation by trained pathologists led to a diagnosis change. Minor salivary gland infiltration may also be revealed in patients affected by myasthenia gravis, sialolithiasis and other autoimmune disorders not associated with sicca symptoms [12].

In addition, the extent of infiltrate in a lip biopsy using the same methodological approach may vary greatly from gland to gland in a single patient. Further, if the density of infiltrate is severe, the foci may become confluent, hindering focus score determination.

Whilst the last studies, in particular the correlation between a higher focus score and the development of lymphoma, suggest stability of the histological lesions over a period of time, this has not been proven in large cohorts. Moreover the sensitivity of focus score is reduced in smokers and in patients taking corticosteroids. The combination of focus score >1 and immunological staining for IgA has been shown to increase the diagnostic specificity for Sjögren syndrome. Indeed, the presence of a focus score >1 and quantitative immunohistological staining of IgA <70%, had greater sensitivity and specificity that the focus score alone.

The focus score, although giving an idea of the extent of the cellular infiltrate, fails to provide discrete data on the foci size (indeed, for larger or confluent foci a focus score of 12 is arbitrarily used). This aspect, while not critically determinant for the histological diagnosis of Sjögren syndrome, could represent a problem for the use of the focus score as an outcome measure in clinical trials in which subtle changes in foci size might not be accurately reported in the focus score. The introduction of additional measurements such as average of focus area, area of lymphocytic infiltration and evaluation of the degree of organization to augment the information provided by the simple focus score is currently debated in the Sjögren syndrome community.

Conclusion

The oral labial minor salivary gland biopsy is a valuable diagnostic tool for the establishment of Sjögren syndrome diagnosis. However, a positive Sjögren syndrome focus score is not diagnostic of Sjögren syndrome by itself, but the results of the biopsy must be correlated with each of the other diagnostic criteria in order to establish an accurate diagnosis. In addition, a number of patients with negative lip biopsy, (focus score less than 1) can end up with a confirmed diagnosis supporting the Sjögren syndrome. Furthermore, the minor salivary gland biopsy is also helpful in excluding other conditions, such as sarcoidosis, which may be associated with a sicca syndrome, or sialosis.

In conclusion, despite the lack of agreement in the parameters considered when evaluating salivary gland biopsies, histology remains the gold standard for diagnosis of Sjögren syndrome and has the potential to become the most reliable biomarker in clinical studies. However, the heterogeneity of the measurements might present the potential risk of compromising the combined analysis of different trials. The current interest in designing clinical trials in Sjögren syndrome will therefore require a combined effort of rheumatologists and oral medicine specialists to discuss these aspects and define consensus guidelines on the methodology and use of the salivary gland biopsy analysis in clinical trials.

This increased awareness will help to reduce the time to diagnosis, to direct the treatment from symptomatic, at the exact etiology behind the disease (tissue specific receptors), and to preserve the health and quality of life of patients with Sjögren syndrome [13].

References


Medication-Related Osteonecrosis of the Jaw (MRONJ): Clinical Manifestations and Radiographic Signs*

Oleksii O. Tymofieiev1,2 and Oleksandr O. Tymofieiev2

1 Chair, Department of Maxillofacial Surgery, Stomatology Institute, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine (ScD, Prof)
2 Associate Professor, Department of Dentistry, Stomatology Institute, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine (ScD, Assoc Prof)

ABOUT ARTICLE
Article history:
Paper received 05 April 2018
Accepted 21 April 2018
Available online 30 September 2018

Keywords:
Chemotherapy
Medication-related osteonecrosis of the jaw (MRONJ)
Biphosphonate-related osteonecrosis of the jaw (BRONJ)
Sequesters
Sequestration
Sequesterectomy

ABSTRACT
Purpose.
To study clinical and radiographic symptoms of chemotherapeutic osteonecrosis of the jaws.

Methods.
The examination is based on a clinical study of 28 patients with medication-related osteonecrosis of the jaw (MRONJ), which appeared after the chemotherapy with bisphosphonates, which was performed after the removal of malignant neoplasms of the maxillofacial region.

Results.
On the basis of the performed examination of the patients, clinical symptoms and radiographic signs of the MRONJ were studied. The methods of MRONJ treatment were described.

Conclusion.
Upon medication-related osteonecrosis of the jaw, a significant destruction of bone tissue is observed, which is accompanied by the formation of sequesters and necrosis in the jaw bone what needs a special surgical tactic upon the MRONJ treatment.

© 2018 OMF Publishing, LLC. This is an open access article under the CC BY licence (http://creativecommons.org/licenses/by-nc/4.0/).

Introduction
Chemotherapy is a method of treating malignant tumors with drugs that have antitumor activity [1, 2]. Surgeons, unfortunately, do not always manage to remove the entire tumor. Sometimes the areas of the affected tissue are not noticed, which can subsequently cause a relapse of the tumor. In these cases it is recommended to use chemotherapy. Influencing the cells of a malignant tumor, chemotherapy drugs, unfortunately, also act on other cells of the human body.

Chemotherapy is prescribed in various regimens. Adjuvant chemotherapy is usually a short course of combined chemotherapy, when drugs are used in large doses in patients without residual manifestations of cancer after radiation or surgical treatment. Its goal is to destroy any remaining cancer cells. Inductive chemotherapy is, as a rule, combined chemotherapy in high doses to induce remission. Supportive chemotherapy is a long-term mode of administration of low doses of drugs in patients in the stage of remission for its preservation by suppressing the growth of the remaining tumor cells.

Thus, there are two regimens of chemotherapy – it is curative and preventive. The treatment regimen is used to treat a tumor. Preventive chemotherapy is performed to suppress hidden foci of the tumor after the application of surgical method and radiotherapy. Chemotherapy does not necessarily lead to a complete cure of the tumor, but it often causes regression of the tumor and allows prolonging the life of the patient. A group of synthetic drugs with antitumor activity is called bisphosphonates.

Bisphosphonates were developed in the XIX century, but for medical purposes they were applied only in the 1960s. For non-medical purposes, they were used to soften water in irrigation systems. The basis for the medical use of bisphosphonates was their ability to prevent the dissolution of hydroxyapatite, the main bone mineral, thereby reducing bone loss.

In pharmacology, bisphosphonates (synonym: diphosphonates) are a class of drugs that prevent bone loss and are used to treat osteoporosis and similar diseases. They are called bisphosphonates, since their molecules contain two phosphonates (PO3). One of the valuable properties of bisphosphonates is that they can be used in cancer diseases characterized by the formation of osteolytic bone metastases, which is due to the inhibition of osteoclastic bone resorption.
of tumors in the bone tissue (these drugs do not allow spreading metastases and reduce pain syndrome). Receiving positive effects with the use of chemotherapy, the doctor has to face complications that occur with side effects, and this complication can be osteonecrosis of the jaw. Bisphosphonates have a retarding effect on the endothelium of the vessels, leading to a decrease in blood flow in the bone tissue [3]. Therefore, osteonecrosis of the jaw when using bisphosphonates is also known as “dead jaw syndrome” or avascular necrosis or aseptic necrosis.

At present, many antitumor drugs, are based on bisphosphonates. A large number of complications are caused by bisphosphonates, which contain the following active substances: zolendronic acid (Zometa, Zolendronate, etc.), pamidronic acid (Arheda, etc.), alendronate sodium (Fosamax, etc.). With oral administration of bisphosphonates, the osteonecrosis of the jaw is practically not found [4]. The frequency of osteonecrosis of the jaw bones with intravenous administration of these drugs ranges from 6.5% to 12.5% [5, 6]. Among these drugs, a special place should be given to the drug Zometa – bisphosphonate of IV generation, the anti-resorptive activity of which exceeds the earlier bisphosphonates (first, second and third generations) more than 1000 times.

The toxicity of antitumor drugs depends on the physical condition of the patient, concomitant diseases (lungs, heart, kidneys, and liver), the dose, the duration of the course of chemotherapy, the nature of the drugs themselves.

The purpose of the survey is to study the clinical features of the clinical course of the osteonecrosis of the jaw (medication-related osteonecrosis of the jaw (MRONJ)) (synonyms: bisphosphonate-related osteonecrosis of the jaw, chemotherapeutic osteonecrosis of the jaw)) in patients after chemotherapeutic treatment with drugs containing bisphosphonates.

**Material and Methods**

A complex clinical examination of 28 patients aged 33 to 79 years with osteonecrosis of the jaw in patients after chemotherapeutic treatment with drugs that contained bisphosphonates was carried out. We have observed patients and surgical interventions both in the Department of Maxillofacial Surgery at Shupyk National Medical Academy of Postgraduate Education and in other surgical departments of Kyiv city and other cities of Ukraine. Observation of this group of patients was carried out for 8 years, i.e. from 2009 to the present. All patients with hospitalization to the Department of Maxillofacial Surgery and the dynamics of the treatment conducted general clinical examination methods, which included: collection of anamnesis, clarification of the nature of complaints, examination, palpation, X-ray of the jaws in different projections, computed tomography, clinical blood tests.

**Results and Analysis**

The most typical beginning of the changes in bone tissue in the maxilla or mandible, with complications with bisphosphonates [9-14], is the non-healing wounds after the teeth extractions, which increase in size with the subsequent exposure of bone tissue or can be exposed to the bone after traumatic damage to the mucosa of the alveolar process (Fig 1).

**FIGURE 1.** (A) Appearance of non-healing wounds (arrows). (B) Noted exposure of the bone tissue (arrow) after a trauma of the alveolar mucosa.

On the maxilla, chemotherapeutic osteonecrosis can seldom take place in the form of a limited focus (focal), but it is more often characterized by a diffuse nature. Characterized by chronic course and the extent of the lesion (more often has a diffuse character). Bone tissue in the area of the pathological focus is exposed within the alveolar process in the area of one (rarely) or several alveoli (more often) of previously removed teeth. Alveoli
are clearly visible on the site of previously removed teeth, the teeth sockets are separated from each other by deformed dental septa, which are covered with a dirty yellow plaque. The bone of the alveolar process is surrounded by a mucous membrane of pale-pink color (more often) or hyperemic (less often), the bony holes are usually filled with a purulent exudate having a foamy appearance (Fig 2). Bone tissue in pathological foci (areas of its outcrop) has a dirty gray, dull, matt or yellow-brown color, and in some places is covered with a touch of dirty and/or gray. Bone tissue always looks “eroded” in the absence of granulation tissue in the pathological foci (Fig 2C). In some areas, between the exposed and deformed bone tissue of the alveolar process of the maxilla may be externally intact, but with exposed necks and even roots of the teeth. The mucous membrane of the mucobuccal fold is pale pink, somewhat thickened and painless. Soft tissues around the exposed bone, from the hard palate and the mucobuccal fold, are thickened and covered with a mucous membrane of both pale pink color (more often) and hyperemic (in places of accumulation of dirty gray plaque). Soft tissue around the pathological focus is infiltrated and painless. Granulation tissue in the exposed areas of the bone is absent. On the computed tomography scans (Fig 3), foci of thickening and expansion of the jaw bone are determined with the formation of sequestrum and inflammatory complications (sinusitis, ethmoiditis, etc.).

On the mandible medication-related osteonecrosis proceeds in chronic form and in prevalence can be limited, or focal and/or diffuse. With a limited form of chronic osteonecrosis of the mandible, an exposed portion of the alveolar ridge can be detected within the area of one or several teeth, the bone has a pale yellow, matt, dull or dirty gray color. The mucous membrane around the exposed area of the alveolar bone is usually pale pink in color.
FIGURE 3. Radiological changes in the bone tissue of the maxilla in patients with medication-related osteonecrosis (A-D). Computed tomography revealed pathological foci are indicated by arrows. (Fig 3 continued on next page.)
FIGURE 3. (cont’d). Radiological changes in the bone tissue of the maxilla in patients with medication-related osteonecrosis (A-D). X-ray revealed pathological foci are indicated by arrows.
The exposed alveoli can be filled with purulent exudate, and the surrounding mucous membrane in places of accumulation of purulent exudate can be hyperemic. With diffuse forms of osteonecrosis of the mandible (this form is more common than limited) the areas of the exposed alveolar bone are captured from three or more alveoli of the neighboring teeth (Fig 4). Bone tissue is exposed not only in the area of the alveolar crest (the visible bone alveoli, which are covered with a dirty-gray, dirty-green or dirty-brown bloom), but also at its base. Alveoli of the teeth are clearly visible on the site of previously removed teeth (Fig 4), the alveoli of the teeth are separated from one another by deformed dental septa, the bone has a dirty yellow, dirty gray or brown (with different shades) color. The mucous membrane surrounding a site of the exposed bone is of a pale pink color, without signs of hyperemia. Presence of foci of granulation tissue in inflammatory foci is usually not detected. On the X-rays of the mandible against the background of osteoporosis foci, areas of rarefaction of bone tissue of different sizes are determined with the formation of sequesters (Fig 5) [15-17]. The peculiarity of the X-ray picture of the osteonecrosis data is that the osteomyelitic areas are revealed in the background of the foci of the osteoporosis of the jaw.

**FIGURE 4.** Appearance of pathological changes in the oral cavity with medication-related osteonecrosis of the mandible (A, B) and in drug addicted patients (C).
FIGURE 5. Radiographic changes (A – plane radiography, B, C – multislice computed tomography scans) in the bone tissue of the mandible in patients with medication-related osteonecrosis (A-C). X-ray revealed pathological foci are indicated by arrows (Fig 5 continued on next page.)
Clinically, medication-related osteonecrosis is distinguished from chronic osteomyelitis, which is found in drug addicts [7] hardly, because this pathology has the same pathogenesis of the development of the disease (Fig 4C). Long-term toxic effects on the body of bisphosphonates (with chemotherapy) and chronic phosphoric intoxication (red phosphorus is a part of the drug “vint”) [7] leads to previously described pathological changes in the jaws and they should be evaluated as chronic osteonecrosis of the jaws. Only by collecting the anamnesis of the disease it is possible to establish the true cause of the development of the osteonecrosis of the jaw. The abolition of the use of bisphosphonates does not lead to an independent elimination of the disease, i.e. to self-healing.

When performing the jaw surgery, the main goal of the operation is not only to remove sequesters and necrotic tissues, but also to remove the non-viable bone tissue. This surgical intervention, in our opinion, should be called wide sequestrectomy with resection (with the latter) of a certain fragment of the jaw. In carrying out sequestrectomy, it can be found that large areas of bone of turbid or muddy-gray (dirty yellow) color did not undergo resection and when bone is bored the latter has a lifeless (marbled) appearance due to the lack of bone vessels in it (Fig 6). In these cases, the surgeon needs to remove the non-viable bone tissue to those parts of the bone until the functioning bone vessels are found with the subsequent maximum possible closure of the bone defect of the jaw with local soft tissues.

We consider it a mistake when, with limited or other forms of MRONJ, surgical treatment results in removal of not only non-viable bone tissue, but removal (resection) of viable bone sites. Only removal (resection) of non-viable areas of bone tissue are needed.

For the more effective treatment of purulent-inflammatory lesions of the soft tissues of the maxillofacial region and neck, antibiotics should always be prescribed (better than the last generation), and modern ointment dressings (with Otlocaine, Miramistin, Niticide, Streptonitol or Pantestine, etc.) should always be applied to purulent wound surfaces), as well as immunostimulating (Hepon, Nucleate, Lysobact [18], etc.) and antifungal drugs.

**Conclusions**

The peculiarity of medication-related osteonecrosis
of the jaws in patients after chemotherapy with bisphosphonates is the extent of the lesion (diffuse nature), the chronic and progressive nature of the clinical course, the exposure of the bone tissue of the alveolar bone (the bone tissue has a non-viable appearance, dull, matt or dirty gray), characterized by the absence of granulation tissue in the pathological focus, the absence of pronounced hyperemia of the mucous membrane (pallor of the mucous membranes), thickening of the alveolar process and soft tissue around jaws, low morbidity, as well as the typical poor healing of post-extraction wounds and low effectiveness of the conventional therapeutic measures [19, 20].

Conflict of Interest
The authors declare no conflict of interest.

Role of the Authors and Co-authors
Oleksii O. Tymofieiev and Olekandr O. Tymofieiev are equally contribute to that paper.

Term of Consent
Written patient consent was obtained from parents to publish the clinical photographs.

Ethical Approval
Approval was obtained from the Medical Ethics Committee of the Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine.

Fundings
No funding was received for this study

Acknowledgments
None.

References
Introduction

Maxillofacial area is one of the most frequent localizations of chronic pain syndromes, which are caused by injuries of the peripheral nerves. Among the latter, the injury of the trigeminal nerve takes the leading place [1-3]. The problem of pain syndromes associated with the trigeminal nerve is very relevant, is difficult to diagnose and has not been adequately studied in relation to the pathogenesis. In search of medical assistance, patients with this pathology are forced to contact many specialists of related fields: neurostomatologists, otolaryngologists, maxillofacial surgeons, dentists, and neurologists.

The maxillofacial area has abundant innervation. We have become accustomed to the fact that after a certain type of surgical intervention in this area, post-operative pains, which are eliminated through the use of analgesic drugs, are expressed to varying degrees, as well as sensitivity dysfunction that lasts for a long time. Often we have to deal with persistent, long-existing pains that can not be eliminated by prescribing analgesics. This fact also helped to analyze the incidence of these syndromes (symptoms) after surgical interventions in various maxillofacial pathologies.

In his daily practice, a dentist faces neurogenic lesions that have clinical manifestations in the facial area. These neurological diseases of the trigeminal nerve branches have not only different clinical manifestations, depending on the severity of nerve damage, but also differ in the mechanism of their occurrence and other factors [4-6]. Attempts to systematize neurogenic lesions of peripheral branches of the trigeminal nerve, in the dental literature, were not found. Unfortunately, we can even note that many neurogenic disorders of the trigeminal nerve system that arise as complications of diseases, as well as after trauma, surgical interventions, are perceived as a clinical symptomatology that can be characteristic of many nosological forms, thus, an adequate medical neurological evaluation, and, consequently, the corresponding treatment are not carried out.

Materials and Methods

We observed 1096 patients with secondary trigeminal neuronal lesions of the trigeminal nerve system who were referred for treatment to the Department of Maxillofacial Surgery, Shupyk National Medical Academy of Postgraduate Education.

All patients underwent general clinical examination methods, which included: examination, palpation, collection of anamnesis, radiography of the bones of...
the facial skeleton, etc. The distribution of patients with localization of the trigeminal nerve neuropathy on the maxilla and mandible by the age and sex is presented in Table 1.

The control group consisted of 35 people – practically healthy people in the same age range (from 17 to 47 years).

**TABLE 1.** Distribution of Patients With Trigeminal Neuropathy in the Examined Groups, Depending on Age and Sex.

<table>
<thead>
<tr>
<th>Observation Group</th>
<th>Total Number of Patients</th>
<th>Age and Sex of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>18-19</td>
</tr>
<tr>
<td>Maxilla</td>
<td>541</td>
<td>M^a M</td>
</tr>
<tr>
<td>Neuralgia</td>
<td>161</td>
<td>10</td>
</tr>
<tr>
<td>Neuralgic neuritis</td>
<td>184</td>
<td>15</td>
</tr>
<tr>
<td>Neuritis</td>
<td>196</td>
<td>17</td>
</tr>
<tr>
<td>Mandible</td>
<td>524</td>
<td>M</td>
</tr>
<tr>
<td>Neuralgia</td>
<td>146</td>
<td>11</td>
</tr>
<tr>
<td>Neuritic neuritis</td>
<td>192</td>
<td>16</td>
</tr>
<tr>
<td>Neuritis</td>
<td>186</td>
<td>14</td>
</tr>
</tbody>
</table>

^a M – Men  
^b F – Females

In addition to general clinical examination methods, we used special methods: the study of the electrophysiological parameters of the peripheral branches of the trigeminal nerve on the hardware-software complex “DIN-1” [7-9], as well as the study of pain, tactile, and temperature sensitivities. All special methods of examination were carried out in the dynamics of treatment of the revealed neurogenic complication.

**Results**

Depending on the mechanism of development of secondary lesions of the trigeminal nerve system, they need to be divided into those that arise in non-tumor and tumor diseases (Table 2) of the maxillofacial region. Non-tumor lesions include neurogenic complications that arise in odontogenic inflammatory diseases of the jaws (periodontitis, periostitis, osteomyelitis, odontogenic subcutaneous granuloma, sinusitis, etc.), non-odontogenic inflammatory diseases (sinusitis, arthritis of temporomandibular joint, nonspecific and specific non-odontogenic inflammatory diseases of the jaws, etc.), traumatic injuries to the facial bones (maxillary and mandibular fractures, fractures of the skull, (hematoma, post-traumatic scars, etc.), postoperative lesions of the peripheral branches of the trigeminal nerve (after sequestrectomy, Caldwell Luc surgery (synonym: highmorotomy) [10], removal of impacted teeth, or/with bone-plastic and reconstructive operations on the facial skeleton, etc.), post-treatment injuries of nerves (trauma with endodontic instruments in the treatment of teeth, compression and toxic effects of the filling material when it is moved bellow tooth root apex, etc.) after dental implants placement (nerve compression with hematoma, displaced bone portion or dental implant, surgical instrument trauma etc.), as well as narrowing of the bone canals where peripheral branches of the trigeminal nerve are located [11-13].

We found that neurogenic disorders are also revealed in tumor diseases of the bones of the face and soft tissues of the maxillofacial area. This group includes neurogenic disorders in tumor-like formations of the jaws (odontogenic and non-odontogenic cysts, epulys, fibrous dysplasia of the jaws, etc.), benign tumors (fibromas, osteomas, osteoblastomas, ameloblastomas, etc.), malignant tumors (osteosarcomas, primary forms of jaw cancer, malignant neuromas, etc.), as well as post-surgical interventions that are carried out to remove tumor-like formations and tumors. Depending on the pathogenesis of neurogenic complications, they have their own characteristics of clinical course, treatment and outcome.

According to the clinical symptoms of secondary lesions of peripheral branches of the trigeminal nerve, we consider them to be divided into three groups (Table 3): neuralgia, neuralgic neuritis and neuritis. Neuralgia, occur when irritating sensitive fibers and are characterized by paroxysmal intense pain along the nerve trunk and its branches. Neuritis is characterized by changes in interstitium, myelin sheath and axial cylinders, and manifested by symptoms of loss of sensitivity in the corresponding zone of innervation. The combination of clinical symptoms of neuralgia and neuritis should be referred to as neuralgic neuritis.

Depending on the severity of clinical neurological symptoms, the disease can be divided into acute,
subacute and chronic (Table 4). This division should be attributed to the neurogenic complications that develop with odontogenic and non-dental diseases, tumor-like formations and tumors.

If neurogenic complications occur after trauma (post-traumatic), after surgical interventions (post-operative), as well as post-implantation or post-consolidation complications, division should be applied to them depending on the timing of patients seeking medical help after the appearance of symptoms of a neurogenic complication (Table 5). According to this principle of all patients, we divided into those with whom neurological treatment was initiated no later than 10 days after the action of the damaging factor (trauma, surgery, compression of the nerve with filling material, etc.) and the appearance of the first symptoms of neurogenic complications. In these cases, we observed no favorable outcomes for more than 90% of those who applied for help. In those cases when patients seek treatment in 11-30 days after the action of the damaging factor and the appearance of the first clinical neurogenic symptoms, the effectiveness of treatment is reduced to 75%, and if treated after 1 month or more – the favorable outcomes are much lower and constitute up to 50% [14-17].

In case of traumatic effects (post-traumatic or postoperative neurogenic lesions of the branches of the trigeminal nerve) it is necessary to use systematization depending on the degree of nerve injury (Table 6). According to the above, the nerve injury, depending on the degree of its damage, should be divided into the following groups: contusion, stretching (with and without rupture of the vascular bundle that accompanies the nerve), incomplete rupture and complete nerve rupture. Each of these groups has its own characteristics of clinical manifestation, course, diagnosis, and treatment. The effectiveness and timeliness of the treatment applied is directly dependent on its adequacy. Therefore, there is a need for early differential diagnosis of the degree of severity of nerve damage.

For topical diagnosis (localization), i.e. depending on the name of the affected sensitive peripheral nerve, they should be divided into: injury of the ophthalmic nerve (frontal, tear, etc.), maxillary nerve (zygomatic, infraorbital, superior alveolar nerves, etc.), and the mandibular (inferior alveolar, auriculotemporal, buccal, and others nerves) nerve (Table 7) [18].
On the basis of studying the clinical symptoms of neuropathic complications in maxillofacial patients and taking into account the phase of nerve damage, we propose to classify secondary neurogenic lesions in the trigeminal nerve system, taking into account the phase (or stage) of pathology development, namely the phase of irritation and the phase of loss of function.

To the phase of irritation of the function, we recommend to include odontogenic algia, hyperalgesia and neuralgia. The phase of irritation is represented by clinical manifestations in the form of odontogenic algia, hyperalgesia, neuralgia.

The phase of loss of function include hypoalgesia, neuritis, secondary disorders in motor and trophic functions. The phase of prolapse corresponds to neuritic manifestations with hypoalgesia, motor and trophic disorders. In the phase of the loss of the function, a subphase should be distinguished in which the features of irritation persist (neural-neuritis should be included in this subphase).

The problem is ambiguous, as many considered it. We believe that the process of neuropathic lesions is one, but in it there are different phases (with the greatest likelihood, even subphases) of pathophysiological changes in the trigeminal nerve system. These phases (subphases) are not static, but are in dynamics and therefore a transition from one phase to another is possible.

Clinical symptoms of secondary lesions in the trigeminal nerve system are manifested in the form of pain of varying severity and/or as a violation of the sensitivity of the soft tissues of the maxillofacial region. These clinical manifestations of neurogenic symptoms are directly related to the dysfunction of the nerve.

Based on the results of a comprehensive survey of more than 1096 patients with a variety of maxillofacial pathology, accompanied by signs of structural lesions in the trigeminal nerve system, we suggest that clinico-pathophysiological approaches should be taken into account in the classification of the corresponding lesions.

**Conclusions**

Offering doctors this classification, we hope that it will help them in the early diagnosis of neurogenic lesions of the trigeminal nerve system in patients, help to correctly assess the degree of nerve damage and timely appoint an adequate treatment [19-22], which will greatly improve the beneficial outcomes of treatment of patients.

**Conflict of Interest**

The authors declare no conflict of interest.

**Role of the Authors and Co-authors**

Oleksii O. Tymofieiev (material collection, concept of the paper and writing)
Olena P. Vesova (material collection)
Natalia O. Ushko (material collection)

**Ethical Approval**

None.
Term of Consent

No needed.

Ethical Approval

Approval was obtained from the Medical Ethics Committee of the Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine.

Fundings

No funding was received for this study

Acknowledgments

None.

References

1. Grechko VE, Sineva NA. Bilateral facial pains upon the trigeminal nerve system (review) [Russian]. Zh Nevrol Psikhiatr Im S S Korsakova 2005;8:1411–7.
3. Treshchinsky AI, Dinaburg AD Neurological syndromes with lesions of the trigeminal nerve [Russian]. Kiev: Zdorovia; 1983.


Obituary for Dr. José Guerrerosantos: A Teacher Who Continues to Live in the Works of His Disciples

Legend of plastic surgery, the great founder has gone. José Guerrerosantos, M.D. (Fig 1), was not only a Director and Plastic Surgeon in Charge, The Jalisco Plastic and Reconstructive Surgery Institute; Professor and Chairman of the Division of Plastic and Reconstructive Surgery, University of Guadalajara Medical College, Guadalajara, Mexico. He was a founding father of the Instituto Jalisciense de Cirugía Reconstructiva (The Jalisco Plastic and Reconstructive Surgery Institute), a hospital affiliated with the University of Guadalajara, Jalisco, Mexico [1]. One of his scientific “children” – Manual of Aesthetic Surgery (editors: Fisher JC, Guerrerosantos J, Gleason M) (Fig 2) is a state of art textbook [2], an immortal masterpiece, which continues to navigate next generations of plastic surgeons in the extremely responsible field of surgery. The sacred Manual, which is a testament for surgeons of different subspecialties. Also, contribution of Professor José Guerrerosantos to the flap of tongue is really helped to lift a flap surgery to the new heights. Professor Guerrerosantos was born as a son of Mexico and will continue to live in his creations, our minds, and the works of his disciples. And it’s very symbolic, that his students and disciples named and still names him the same name as a Jesus was called… “a Teacher”…

FIGURE 1. Translation of the Instagram post of Dr. Julio Palacios (Mexico City, Mexico): “The one who prudent meditates, many sorrows avoids”... José Guerrerosantos (1932-2017) – Nació en Jalisco, México el 26 de Febrero, egresó de la Escuela de Medicina de la Universidad de Guadalajara y continuó su formación en la Universidad de Illinois, en Chicago. – En 1976 fundó el Instituto Jalisciense de Cirugía Reconstructiva.
- Publicó múltiples artículos científicos entre los que destacan el del colgajo de lengua y el tratamiento del platisma, entre otros.
- “El Maestro” es gratamente recordado por sus alumnos como un ser humano excepcional, que siempre mantuvo el afán de compartir lo que sabía.
#cirugiaplastica #plasticsurgery #plasticsurgeon #cirujanoestetico #maestro #jalisco #mexico #iivanabelikeyou #cirujiareconstructiva

FIGURE 1. “The one who prudent meditates, many sorrows avoids”... José Guerrerosantos (1932-2017) – he was born in state Jalisco (Mexico) on February 26. Graduated from the School of Medicine of the University of Guadalajara (Mexico) and continued his training at the University of Illinois (Chicago, IL, USA). In 1976 he founded the Jalisco Plastic and Reconstructive Surgery Institute [1] (Guadalajara, state Jalisco, Mexico.)
- Published multiple scientific articles among which stand out the tongue flap and the platysma treatment, among others.
- “El Maestro” is pleasantly remembered by his students as an exceptional human being, who always maintained the desire to share what he knew.”

References


Julio Palacios Juárez, MD
Mexico City, Mexico
drpalacios.cirplast@icloud.com
Instagram: drjuliopalacios

Ievgen I. Fesenko, DDS, PhD
Managing Editor
Kyiv, Ukraine
i.i.fesenko@dtjournal.org
Instagram: dr_eugenfesenko
Future Events
for 2018-2021

2018

Plastic Surgery The Meeting
September 28 – October 2, 2018
Chicago, Illinois, USA
www.plasticsurgery.org

The 10th Congress of the Baltic Orthodontic Association
October 4 – October 7, 2018
Vilnius, Lithuania
www.boa2018.com

122 American Academy of Otolaryngology Annual Meeting (AAO-HNSF & OTO Expo 2017)
October 7 – 10, 2018
Atlanta, Georgia, USA
www.entannualmeeting.org

100th Annual Meeting of American Association of Oral and Maxillofacial Surgeons Scientific Sessions & Exhibition
October 8 – 13, 2018
Chicago, Illinois, USA
www.aoms.org

Association of Oral & Maxillofacial Surgeons of India 43rd Annual Conference 2018 (AOMSI 2018)
October 11 – 13, 2018
Chennai, India
www.43chennai.aomsi.com

13th Asian Congress on Oral and Maxillofacial Surgery
November 8 – 11, 2018
Taipei, Taiwan
www.2018acoms.com

Timothy A. Turvey Master Class in Orthognathic Surgery (Fig 2A)
October 26, 2018
Buenos Aires, Argentina
Email: sac@aoa.org.arg

Ninth William H. Bell Lectureship: Overcoming Obstacles in Orthognathic Surgery (Fig 2B)
November 16-17, 2018
Houston, Texas, USA
www.events.houstonmethodist.org/bell-lectureship

1st European Arnett Orthognathic Surgery Forum Symposium (Fig 3)
November 16-17, 2018
Madrid, Spain
Email: info@nemotec.com

14th Congress of Latin American Society of the Oral-Maxillo-Facial Rehabilitation (Fig 1)
(XIV Congreso de la Sociedad Latinoamericana de Rehabilitación Buco Maxillo Facial)
November 20 – 23, 2018
Punta del Este, Uruguay
www.bmf2018puntadeleste.com

FIGURE 1. Instagram posts of Congresobmf2018 (Punta del Este, Uruguay) notes about 14th Congress of Latin America Society of the Oral-Maxillo-Facial Rehabilitation in November 20-23, 2018 (Punta del Este, Uruguay).
Orthognathic Surgery Events in October-November 2018

FIGURE 2. (A) Cropped Instagram post of Trainee.sacytbmf notes about Master Class in Orthognathic Surgery by Timothy A. Turvey, DDS, PhD, FAACS, Prof (Chapel Hill, NC, USA), October 26, 2018 (Buenos Aires, Argentina). Register: sac@aoa.org.arg. (B) Cropped Instagram post of Dr. Jose Sandro P. Silva, DDS, PhD (Natal, Brazil) notes about Ninth William H. Bell Lectureship: Overcoming Obstacles in Orthognathic Surgery, November 16-17, 2018 (Houston, Texas, USA). Program Directors: Jaime Gateno, DDS, MD; James Xia, MD, PhD. Register: www.events.houstonmethodist.org/bell-lectureship

FIGURE 3. Instagram posts (A, B) of Nemotec (Madrid, Spain) notes about 1st European Arnett Orthognathic Surgery Forum Symposium in November 16-17, 2018 (Madrid, Spain). The speakers of the Forum are: William G. Arnett (USA), Domingo Martin (Spain, Instagram: domingomartinasdoto), Elisabetta Grendene (Italy), Octavio Cintra (Brazil, Instagram: octaviocintra), Richard Roblee (USA, Instagram: drrichardtoblee), Antonio d’Agostino (Italy), Jeffrey McClendon (USA), Nico Vrijens (Netherlands), Renato Cocconi (Italy, Instagram: renatococconi), Bruno Ardaua (Spain), Mirco Raffini (Italy), Douglas L. Knight (USA), Julio Cifuentes (Chile), Lorenzo Trevisiol (Italy). More information: info@nemotec.com
2019

24rd International Conference on Oral and Maxillofacial Surgery (Fig 4)
May 21 – 24, 2019
Rio de Janeiro, Brazil
www.icoms2019.com.br

18th Meeting of the International Society of Craniofacial Surgery
September 16 – 19, 2019
Paris, France
www.iscfs.org

2021

14th Quadrennial International Facial Nerve Symposium
August, 2021
South Korea
www.internationalfacialnerve.org

Submission of Articles

Papers for the Publication
• original papers
• clinical cases (case reports)
• surgical notes
• radiological notes
• reports of new equipment, instruments or technical innovations
• journal or book reviews
• reviews of other journals articles
• letters to the Editor

Article and Abstracts
Article must be written in English.
The authors from the Russian-speaking countries must send an abstract of the article in Russian. The authors from Ukraine must send an abstract of the article in Ukrainian and Russian.
One co-author is denominated as the corresponding author with all contact details:
• Postal address (ZIP code of a country, City, Street, phone and fax number)
• E-mail address
The abstract should include full title of the article, full names and surnames of the co-authors, scientific degree, specialty. Also the abstract should include short information about article content: purpose, material and methods, results, conclusions. Example how the Abstract should be looked like the authors can get from the published articles in current issue.

Figures and Tables
Photographs, CT and MRI images, sonograms should be submitted in original with resolution of at least 300 dpi and saved in JPEG or TIFF file format.

Fundings
The authors should indicate the sources of funding that were allocated for the preparation of the article, if such were the case.

Conflicts of Interest
At the end of the article the authors should specify about conflicts of interest (e.g., no conflict of interest).

Role of Co-authors in Writing
After specifying conflicts of interest the role of co-authors in writing of the article (concept and design of the study; material collection, material processing, statistical data processing, writing text, editing, etc.) should be designated.

Patient Consent
Written patient consent should be obtained to publish the clinical images of the patients.

Acknowledgments
The authors can acknowledge the persons or institutions which they helped or useful in writing an article.

The Journal is recommended to use that internet source for the articles preparing according to Vancouver References Style: http://libguides.murdoch.edu.au/Vancouver/journal

Examples How to Form a Reference List
List all references in numerical order in the text.
Making a list of references from articles, books, internet links, etc.:
Example for the articles:

Example for the articles with more than three authors:

Example for the articles from the Journal Supplement:

or

Examples for the book chapters:

Example for the books:

Example for the PhD/ScD work (dissertation for candidate/doctor of science):

Example for references in Cyrillic:


Examples for the internet links:


Example for conference paper in print proceedings:
**Example for conference paper from the internet:**

**Example for A-V materials (DVD):**

**Example for A-V materials (YouTube/Vimeo video):**

**Example for A-V materials (Video recording):**

**Example for Readers/Study Guides:**

**Example for newspaper articles in print:**

**Example for newspaper article from the internet:**

**Example for conversation citation:**
In a conversation with a colleague from the School of Population Health (Jameson LI 2002, oral communication, 7th August)...

**Example for e-mail citation:**
Smith P. New research projects in gastroenterology [online]. E-mail to Matthew Hart (mh@hospital.wa.gov.au) 2000 Feb 5 [cited 2000 Mar 17].

**Spelling and Grammar Check**
The article should be 'spell checked' and 'grammar checked.' You can use American or British usage, but do not use mixture of them. Authors for whom English is not their native language should add an editing certificate (the international company that can provide editing is: www.enago.com).

**Free Access for All Articles**
The journal offers the free access to all articles guiding by the main principle of the journal policy, to give a possibility to colleagues from all countries (even from low-income) to use data for the development of specialties related with Oral and Maxillofacial Area.

Editorial of the Journal independently assigns for the articles Index of the Universal Decimal Classification (UDC) according to the requirements of Higher Attestation Commission of Ukraine and Digital Object Identifier (DOI) according to the international standards.

**Questions?**
i.i.fesenko@dtjournal.org
Mission Statement of the Association
We unite, lead, and develop the maxillofacial community to accelerate theoretical and practical movement forward and improve worldwide.

Address and Contacts
4-A Professor Pidvysotskogo Street, Kyiv 01103, Ukraine
Tel., fax: +38 (044) 528 35 17.
E-mail: info.uamos@gmail.com
www.uamos.org

July 2018 – September 2018

Officers
Oleksii O. Tymofieiev (Kyiv, Ukraine)  
President
Iryna G. Lisova (Kharkiv, Ukraine)  
Vice President – Salivary Glands Diseases/Tumors
Andrii V. Kopchak (Kyiv, Ukraine)  
Vice President – Jaws Fractures
Liudmyla M. Iakovenko (Kyiv, Ukraine)  
Vice President – Pediatric Maxillofacial Surgery
Volodymyr S. Protsyk (Kyiv, Ukraine)  
Vice President – Head & Neck Oncological Surgery
Yan E. Vares (Lviv, Ukraine)  
Vice President – Orthognathic Surgery

Olena P. Vesova (Kyiv, Ukraine)  
Vice President – Trigeminal/Facial Nerve Trauma
Anatolii G. Guliuk (Odessa, Ukraine)  
Vice President – Cleft Surgery
Natalia O. Ushko (Kyiv, Ukraine)  
Vice President – Graduate Education
Anatolii M. Potapchuk (Uzhhorod, Ukraine)  
Vice President – Postgraduate Education
Kostiantyn Ya. Peredkov (Kyiv, Ukraine)  
Vice President and Secretary-Treasurer
Ievgen I. Fesenko (Kyiv, Ukraine)  
Technical Director

Council
Roman O. Mamonov (Kyiv, Ukraine)
Pavlo I. Tkachenko (Poltava, Ukraine)

International Council
Zurab Chichua (Tbilisi, Georgia)
Chingiz R. Ragimov (Baku, Azerbaijan)
Adnan A. Jezzini (Beirut, Lebanon)
Mazen S. Tammimi (Amman, Jordan)
Disclaimer

The statements and opinions expressed in publications of the Journal are solely those of the authors and not of the Ukrainian Association for Maxillofacial and Oral Surgeons (UAMOS). Establishing the integrity of third party resources, such as data repositories located on external websites and servers, used and cited in submissions is the responsibility of the author. All submissions are subject to external peer review as directed by the journal editors, other than UAMOS Statements, which are reviewed by the UAMOS and selected outside experts. The Editors are not permitted to engage in discussions about Journal content for forthcoming issues with agencies involved in soliciting advertisements, or companies purchasing advertising space. The UAMOS does not evaluate advertised products or services nor assess advertising claims. Neither the appearance of advertising in publications of the UAMOS, nor reference to a product within the same, constitutes a guarantee or endorsement of the quality or value of such product or of the claims made for it by its manufacturer. Advertisements are randomly placed, and there is no predetermined relationship between the content and the advertisement. The UAMOS reserves the right to decline or refuse advertisements.
The 10th Congress of the Baltic Orthodontic Association

4-7 October, 2018
Crowne Plaza Vilnius Hotel, Vilnius, Lithuania

SAVE THE DATE FOR BOA 2018!

Skeletal anchorage
relevant to orthodontists, oral surgeons and all dentists involved in multidisciplinary treatment.
Skeletal anchorage
relevant to orthodontists, oral surgeons and all dentists involved in multidisciplinary treatment.

BOA 2018
with Plenary Speakers:

Hugo De Clerck
Belgium

Giorgio Iodice
Italy

Kee-Joon Lee
South Korea

Heinz Winsauer
Austria

Simonas Grybauskas
Lithuania

Dalia Latkauskiene
Lithuania

BOA 2018 Congress Secretariat
info@boa2018.com
www.boa2018.com
AN INTEGRAL COMPONENT OF THE TREATMENT OF PAIN AND INFLAMMATION IN THE ORAL CAVITY IN 60 COUNTRIES WORLDWIDE!

- JAWS FRACTURES
- IMPLANTS PLACEMENT
- WOUNDS OF ORAL CAVITY

LOCAL ANESTHETIC AND ANTI-INFLAMMATORY EFFECT

SUMMARY OF PRODUCT CHARACTERISTICS

NAME OF THE MEDICINAL PRODUCT: Tantum Verde 0.15% mouthwash, QUALITATIVE AND QUANTITATIVE COMPOSITION. Each 100 ml contains active ingredient: benzylamine hydrochloride 0.15 g (equivalent to 0.134 g of benzylamine).

Therapeutic indications: Treatment of symptoms such as irritation/inflammation including those associated with pain in the oropharyngeal cavity (e.g., gingivitis, stomatitis and pharyngitis), including those resulting from conservative or extracting dental therapy. Protocol and method of administration: Pour 15 ml of Tantum Verde mouthwash into the measuring cup, 2-3 times per day, using 6-8 ml of the solution. If suitable, add 15 ml of water to the graduated cup. Do not exceed the recommended dosage. Contraindications: Hypersensitivity to benzylamine or to any of the excipients. PHARMACOLOGICAL PROPERTIES. Pharmacodynamic properties. Pharmacotherapeutic group: Pharmaceutical drugs: other agents for local oral treatments. ATC code: A01AB01. Clinical studies demonstrate that benzylamine is effective in relieving suffering from local irritations of the mouth and pharynx. In addition, benzylamine possesses a moderate local anesthetic effect. Pharmacokinetic properties. Absorption: Absorption through the oropharyngeal mucosa is demonstrated by the presence of measurable quantities of benzylamine in human plasma. These levels are insufficient to produce systemic effects. Distribution. When applied locally, benzylamine has been shown to accumulate in inflamed tissues where it reaches effective concentrations because of its capacity to penetrate the epithelial lining.

Information about medicines. Information for health care professionals for use in professional activities.

1. Инструкция для медицинского персонала. Жевательный пластырь "Тантум Верде", российский раздел, РПРУ/0000/01/001, зарегистрирован в Министерстве здравоохранения РФ, декрет № 236 от 01.10.2005.

Clinical andCT images are courtesy of: Rostov Osteopathic Department of Oral & Maxillofacial Surgery, RPHU "My Medical University", Rostov-on-Don; DNEC "SCIENCE - Scientific Center of Dentistry & Ultrasound Surgery" Kyiv, Ukraine.